Surgical treatment of gastric cancer: 15-year follow-up inationwide Dutch D1D2 trial

Lancet Oncology, The 11, 439-449

DOI: 10.1016/s1470-2045(10)70070-x

Citation Report

#	Article	IF	Citations
1	Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology. Recent Patents on DNA & Gene Sequences, 2010, 4, 202-209.	0.7	12
2	Recurrent patterns and factors involved in node-negative advanced gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2010, 22, 285-290.	0.7	0
3	Laparoscopic Surgery for Gastric Cancer: A Collective Review with Meta-Analysis of Randomized Trials. Journal of the American College of Surgeons, 2010, 211, 677-686.	0.2	116
4	Roux-en-Y gastroenteroanastomosis in the treatment of stenosing and advanced gastric adenocarcinoma. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2010, 23, 90-93.	0.5	1
5	Gastric Cancer in Poland – Clinical Characteristics and Results of Surgery. Digestive Surgery, 2010, 27, 409-416.	0.6	2
8	Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait?. Lancet Oncology, The, 2010, 11, 404-405.	5.1	5
9	Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 2011, 29, 4387-4393.	0.8	1,186
11	Guidelines for the management of oesophageal and gastric cancer. Gut, 2011, 60, 1449-1472.	6.1	570
12	The Roles of Surgical Oncologists in the New Era – Minimally Invasive Surgery for Early Gastric Cancer and Adjuvant Surgery for Metastatic Gastric Cancer. Pathobiology, 2011, 78, 343-352.	1.9	41
13	Gastric cancer: So much has changed for surgeons!. Journal of Visceral Surgery, 2011, 148, 1-2.	0.4	6
14	Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics Journal, 2011, 11, 81-92.	0.9	78
15	Combination of Ex Vivo Sentinel Lymph Node Mapping and Methylene Blue-Assisted Lymph Node Dissection in Gastric Cancer: A Prospective and Randomized Study. Annals of Surgical Oncology, 2011, 18, 1860-1868.	0.7	11
16	Cancer de l'estomac. , 2011, , 341-358.		O
17	Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer. Expert Review of Anticancer Therapy, 2011, 11, 503-506.	1.1	7
18	Hospital volume and survival in oesophagectomy and gastrectomy for cancer. European Journal of Cancer, 2011, 47, 2408-2414.	1.3	71
19	Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection. European Journal of Surgical Oncology, 2011, 37, 305-311.	0.5	59
20	Lymph node examination among patients with gastric cancer: Variation between departments of pathology and prognostic impact of lymph node ratio. European Journal of Surgical Oncology, 2011, 37, 488-496.	0.5	28
22	<i>D2 Lymph Node Dissection Improves Staging in Patients with Gastric Adenocarcinoma</i> Surgeon, 2011, 77, 1326-1329.	0.4	11

#	Article	IF	Citations
23	Lymph Node Dissection in Gastric Carcinoma. , 0, , .		1
24	Lymph Node Dissection in Curative Gastrectomy for Advanced Gastric Cancer. International Journal of Surgical Oncology, 2011, 2011, 1-8.	0.3	37
25	Meta-Analysis of D1 Versus D2 Gastrectomy for Gastric Adenocarcinoma. Annals of Surgery, 2011, 253, 900-911.	2.1	112
26	Clinical Implications of the Histologically and Immunohistochemically Detected Solitary Lymph Node Metastases in Gastric Cancer. Scandinavian Journal of Surgery, 2011, 100, 174-180.	1.3	6
27	BLADDER TUMOURS: TIME FOR A PARADIGM SHIFT?. BJU International, 2011, 107, 1543-1545.	1.3	4
28	Laparoscopic versus open gastrectomy for early distal gastric cancer: a meta-analysis. ANZ Journal of Surgery, 2011, 81, 673-680.	0.3	44
29	Chemotherapy for Operable Gastric Cancer: Current Perspectives. Indian Journal of Surgical Oncology, 2011, 2, 334-342.	0.3	7
30	High Accuracy of Multislices Computed Tomography (MSCT) for Para-Aortic Lymph Node Metastases from Gastric Cancer: A Prospective Single-Center Study. Annals of Surgical Oncology, 2011, 18, 2265-2272.	0.7	38
31	Laparoscopic and robotic-assisted D2 surgery for gastric cancer: a reality in Europe?. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2414-2416.	1.3	0
32	Proximal gastric cancer: advances of laparoscopic surgery. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2761-2763.	1.3	3
33	Totally laparoscopic total gastrectomy and the challenge of esophagojejunostomy. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 3468-3469.	1.3	6
34	Sentinel node biopsy in laparoscopic surgical oncology. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 3713-3714.	1.3	4
35	Extended lymphadenectomy improvement of overall survival of gastric cancer patients with perigastric node metastasis. Langenbeck's Archives of Surgery, 2011, 396, 615-623.	0.8	17
36	Extended lymph node dissection for gastric cancer from a European perspective. Gastric Cancer, 2011, 14, 396-398.	2.7	12
37	Meta-analysis of randomized controlled trials comparing D2 and D4 lymphadenectomy for gastric cancer. European Surgery - Acta Chirurgica Austriaca, 2011, 43, 255-261.	0.3	1
39	Gastric cancer – still many questions to be solved. Memo - Magazine of European Medical Oncology, 2011, 4, 71-74.	0.3	4
40	D2 Lymphadenectomy (Over-D1 Dissection) for Advanced Gastric Cancer Is an Evidence-Based Procedure. Journal of Gastrointestinal Surgery, 2011, 15, 2122-2123.	0.9	2
41	Evaluation of Postoperative Pancreatic Fistula After Total Gastrectomy with D2 Lymphadenectomy by ISGPF Classification. Journal of Gastrointestinal Surgery, 2011, 15, 1969-1976.	0.9	42

#	ARTICLE	IF	CITATIONS
42	Open vs robotâ€assisted laparoscopic gastric resection with D2 lymph node dissection for adenocarcinoma: a caseâ€control study. International Journal of Medical Robotics and Computer Assisted Surgery, 2011, 7, 452-458.	1.2	76
43	Do all roads lead to Rome? Routes to metastasis development. International Journal of Cancer, 2011, 128, 2511-2526.	2.3	119
44	Changing clinical and pathological features of gastric cancer over time. British Journal of Surgery, 2011, 98, 1273-1283.	0.1	74
49	Capecitabine in gastric cancer. Expert Review of Anticancer Therapy, 2011, 11, 1791-1806.	1.1	11
50	Gastric malignancy. Current Opinion in Gastroenterology, 2011, 27, 583-587.	1.0	2
51	Robotic Gastrectomy as an Oncologically Sound Alternative to Laparoscopic Resections for the Treatment of Early-Stage Gastric Cancers. Archives of Surgery, 2011, 146, 1086.	2.3	177
52	Present and Future Status of Gastric Cancer Surgery. Japanese Journal of Clinical Oncology, 2011, 41, 307-313.	0.6	87
54	Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease. Gastrointestinal Cancer: Targets and Therapy, 2011, , 41.	5.5	1
55	Lymph Node Metastasis of Gastric Cancer. Cancers, 2011, 3, 2141-2159.	1.7	48
56	Challenges with Demographic Disparities in Gastric Cancer Care and Survival: Spectral Rather than Black and White. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 221-222.	1.1	0
57	Nomogram Predicting Long-Term Survival After D2 Gastrectomy for Gastric Cancer. Journal of Clinical Oncology, 2012, 30, 3834-3840.	0.8	312
58	Treatment of resectable gastric cancer. Therapeutic Advances in Gastroenterology, 2012, 5, 49-69.	1.4	70
59	Losses of Chromosome 5q and 14q Are Associated with Favorable Clinical Outcome of Patients with Gastric Cancer. Oncologist, 2012, 17, 653-662.	1.9	27
60	Recent Advances in Diagnosis and Treatment for Malignancies of the Gastrointestinal Tract. Digestion, 2012, 85, 95-98.	1.2	7
61	Impact of Histopathology on the Outcome of D1/D2 Gastrectomies with R0 Resection. Digestion, 2012, $86,67-73$ .	1.2	1
62	Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy. International Journal of Surgical Oncology, 2012, 2012, 1-7.	0.3	8
63	Current Management and Future Strategies of Gastric Cancer. Yonsei Medical Journal, 2012, 53, 248.	0.9	57
64	The End of Limited Lymphadenectomy in Gastroesophageal Cancer Surgery?. Archives of Surgery, 2012, 147, 746.	2.3	0

#	ARTICLE	IF	CITATIONS
65	Survival after Adjuvant Chemoradiotherapy or Surgery Alone in Resectable Adenocarcinoma at the Gastro-Esophageal Junction. Scandinavian Journal of Surgery, 2012, 101, 26-31.	1.3	24
67	Laparoscopic Versus Open Distal Gastrectomy for Gastric Cancer. Annals of Surgery, 2012, 255, 446-456.	2.1	325
68	An update of adjuvant treatments for localized advanced gastric cancer. Clinical Investigation, 2012, 2, 1101-1108.	0.0	3
69	Prognostic Value of the 7th AJCC/UICC TNM Classification of Noncardia Gastric Cancer. Annals of Surgery, 2012, 255, 486-491.	2.1	124
71	Molecular-Based Decision Making for Personalized Cancer Management. , 2012, , .		0
73	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, The, 2012, 379, 315-321.	6.3	1,422
74	Improving Outcomes After Gastroesophageal Cancer Resection. Archives of Surgery, 2012, 147, 738.	2.3	32
75	Evaluation of serum highâ€density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1635-1640.	1.4	49
76	PG 9.03 Can adjuvant radiochemothrapy replace extended lymph node dissection?. European Journal of Cancer, 2012, 48, S9-S10.	1.3	0
77	PG 9.04 Oesophagogastric cancer: A case for perioperative chemotherapy. European Journal of Cancer, 2012, 48, S10.	1.3	4
78	PG 10.01 Predicting the response to neoadjuvant chemotherapy I (Who profits from neoadjuvant) Tj ETQq0 0 0 rş	gBT <sub>3</sub> /Over	lock 10 Tf 5
79	PG 10.02 Predicting the response to neoadjuvant chemotherapy II (Ability of pretherapeutic parameters) Tj ETQq1 Journal of Cancer, 2012, 48, S10.	1 0.7843 1.3	314 rgBT /0 0
80	PG 10.03 Lessons from the GASTRIC metaanalysis of adjuvant treatment. European Journal of Cancer, 2012, 48, S10-S11.	1.3	0
82	Phase 3 Trial of Postoperative Chemotherapy Alone Versus Chemoradiation Therapy in Stage III-IV Gastric Cancer Treated With RO Gastrectomy and D2 Lymph Node Dissection. International Journal of Radiation Oncology Biology Physics, 2012, 84, e585-e592.	0.4	94
83	Gastric carcinoma with osteoblastic differentiation. International Journal of Surgery Case Reports, 2012, 3, 516-519.	0.2	7
84	Surgery for Gastric Cancer: What the Trials Indicate. Surgical Oncology Clinics of North America, 2012, 21, 79-97.	0.6	4
85	Preoperative and Postoperative Chemotherapy for Gastric Cancer. Surgical Oncology Clinics of North America, 2012, 21, 99-112.	0.6	20
86	Nodal Counts on MDCT as a Surrogate Marker for Surgical Curability in Gastric Cancer. Annals of Surgical Oncology, 2012, 19, 2465-2470.	0.7	15

#	Article	IF	CITATIONS
87	The New American Joint Committee on Cancer/International Union Against Cancer Staging System for Adenocarcinoma of the Stomach: Increased Complexity without Clear Improvement in Predictive Accuracy. Annals of Surgical Oncology, 2012, 19, 2443-2451.	0.7	57
88	Staging Gastric Cancer Patients after Complete Surgical Resection: Which System Should We Use?. Annals of Surgical Oncology, 2012, 19, 2423-2425.	0.7	2
89	Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: Implications for postoperative radiotherapy. Radiotherapy and Oncology, 2012, 104, 367-373.	0.3	48
90	Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. European Journal of Cancer, 2012, 48, 1004-1013.	1.3	134
91	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer, 2012, 48, 2941-2953.	1.3	129
92	Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. European Journal of Surgical Oncology, 2012, 38, 143-149.	0.5	34
93	Metastatic lymph node ratio versus number of metastatic lymph nodes as a prognostic factor in gastric cancer. European Journal of Surgical Oncology, 2012, 38, 497-502.	0.5	32
94	Mortality After Esophageal and Gastric Cancer Resection. World Journal of Surgery, 2012, 36, 2630-2636.	0.8	12
95	Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World Journal of Surgical Oncology, 2012, 10, 195.	0.8	20
97	Standard D2 and Modified Nodal Dissection for Gastric Adenocarcinoma. Surgical Oncology Clinics of North America, 2012, 21, 57-70.	0.6	7
98	Importance of and Adherence to Lymph Node Staging Standards in Gastrointestinal Cancer. Surgical Oncology Clinics of North America, 2012, 21, 407-416.	0.6	0
99	Gastrointestinal System Cancers. , 2012, , 357-406.		0
100	Ultrasonic Scalpel for Gastric Cancer Surgery: a Prospective Randomized Study. Journal of Gastrointestinal Surgery, 2012, 16, 1840-1846.	0.9	27
102	A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer. Gastric Cancer, 2012, 15, 89-99.	2.7	33
103	A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer, 2012, 15, 60-69.	2.7	89
104	How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer, 2012, 15, 70-88.	2.7	83
105	Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1425-1434.	3.3	51
106	Expanding laparoscopic gastrectomy for gastric cancer outside Korea and Japan. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 3700-3701.	1.3	1

#	ARTICLE	IF	CITATIONS
107	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 2012, 11, 363-369.	0.9	71
109	Optimal Surgery for Gastric Cancer: Is More Always Better?. Recent Results in Cancer Research, 2012, 196, 215-227.	1.8	9
111	Radiotherapy for tumors of the stomach and gastroesophageal junction – a review of its role in multimodal therapy. Radiation Oncology, 2012, 7, 192.	1.2	18
112	Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center. Radiation Oncology, 2012, 7, 169.	1.2	18
113	D2 dissection in laparoscopic and open gastrectomy for gastric cancer. World Journal of Gastroenterology, 2012, 18, 833.	1.4	36
114	Lymph node dissection for gastric cancer: a critical review. Oncology Reviews, 2012, 6, 12.	0.8	5
115	Current management of gastric cancer. Revista Espanola De Enfermedades Digestivas, 2012, 104, 134-141.	0.1	25
116	Postoperative Adjuvant Radiotherapy for Patients with Gastric Adenocarcinoma. Journal of Gastric Cancer, 2012, 12, 205.	0.9	3
117	Comparisons of Gastric Cancer Treatments: East vs. West. Journal of Gastric Cancer, 2012, 12, 55.	0.9	121
118	Resultados da gastrectomia D2 para o câncer gástrico: dissecção da cadeia linfática ou ressecção linfonodal múltipla?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2012, 25, 161-164.	0.5	13
119	Update of Adjuvant Chemotherapy for Resected Gastric Cancer. Journal of Gastric Cancer, 2012, 12, 3.	0.9	17
122	Recent advances and future challenges in the treatment of upper gastrointestinal malignancies. Memo - Magazine of European Medical Oncology, 2012, 5, 157-160.	0.3	0
123	Splenic infarction following conventional open gastrectomy in patients with gastric malignancy: a CT-based study. Abdominal Imaging, 2012, 37, 609-615.	2.0	2
124	Identification of Risk Factors for Esophagojejunal Anastomotic Leakage after Gastric Surgery. World Journal of Surgery, 2012, 36, 1617-1622.	0.8	92
125	Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 1813-1821.	1.3	17
126	Intra-abdominal infectious complications following gastrectomy in patients with excessive visceral fat. Gastric Cancer, 2012, 15, 206-212.	2.7	56
127	Quantum-dots based simultaneous detection of multiple biomarkers of tumor stromal features to predict clinical outcomes in gastric cancer. Biomaterials, 2012, 33, 5742-5752.	5.7	45
129	Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbeck's Archives of Surgery, 2012, 397, 45-55.	0.8	18

#	Article	IF	CITATIONS
130	Randomized trials and quality assurance in gastric cancer surgery. Journal of Surgical Oncology, 2013, 107, 298-305.	0.8	8
131	Clinical trials in gastric cancer and the future. Journal of Surgical Oncology, 2013, 107, 289-297.	0.8	8
132	D1 versus D2 lymphadenectomy for gastric cancer. Journal of Surgical Oncology, 2013, 107, 259-264.	0.8	77
133	Minimally invasive approaches for gastric cancerâ€"Japanese experiences. Journal of Surgical Oncology, 2013, 107, 282-288.	0.8	45
134	Surgical approaches to gastric cancer. Journal of Surgical Oncology, 2013, 107, 250-258.	0.8	20
135	Laparoscopy-assisted gastrectomy with D2 lymph node dissection for advanced gastric cancer without serosa invasion: a matched cohort study from South China. World Journal of Surgical Oncology, 2013, 11, 4.	0.8	30
136	Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinic outcomes of gastric cancer. Journal of Translational Medicine, 2013, 11, 153.	cal 1.8	27
137	Outcomes among patients treated for gastric adenocarcinoma during the last decade. Journal of Surgical Oncology, 2013, 107, 752-757.	0.8	11
138	Long-Term Survival After Gastrectomy for Cancer in Randomized, Controlled Oncological Trials: Comparison between West and East. Annals of Surgical Oncology, 2013, 20, 2328-2338.	0.7	81
139	Extended Lymphadenectomy in Gastric Cancer Is Debatable. World Journal of Surgery, 2013, 37, 1773-1777.	0.8	30
140	Lymph Node Dissection in Resectable Advanced Gastric Cancer. Digestive Surgery, 2013, 30, 96-103.	0.6	28
141	D2 Lymphadenectomy with Surgical Ex Vivo Dissection into Node Stations for Gastric Adenocarcinoma Can Be Performed Safely in Western Patients and Ensures Optimal Staging. Annals of Surgical Oncology, 2013, 20, 2991-2999.	0.7	25
142	Extended Lymphadenectomy in Gastric Cancer Is Crucial. World Journal of Surgery, 2013, 37, 1768-1772.	0.8	7
144	Race and Correlations Between Lymph Node Number and Survival for Patients with Gastric Cancer. Journal of Gastrointestinal Surgery, 2013, 17, 471-481.	0.9	14
145	Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances. Medical Oncology, 2013, 30, 651.	1.2	20
146	National outcomes and uptake of laparoscopic gastrectomy for cancer in England. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 3348-3358.	1.3	23
147	Early results of a modified splenic hilar lymphadenectomy in laparoscopy-assisted total gastrectomy for gastric cancer with stage cT1-2: a case–control study. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 1923-1931.	1.3	22
148	Long-term comparison of laparoscopy-assisted distal gastrectomy and open distal gastrectomy in advanced gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 462-470.	1.3	57

#	ARTICLE	IF	Citations
149	Adjuvant and Neoadjuvant Therapy for Gastric Cancer. Current Treatment Options in Oncology, 2013, 14, 311-320.	1.3	17
150	Oncologic Outcomes of Laparoscopy-Assisted Distal Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 2676-2682.	0.7	29
151	Function-Preserving Gastrectomy for Early Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 2683-2692.	0.7	92
152	Is There Any Role of Additional Retropancreatic Lymph Node Dissection on D2 Gastrectomy for Advanced Gastric Cancer?. Annals of Surgical Oncology, 2013, 20, 2669-2675.	0.7	15
153	Impact of perioperative hemoglobin levels on postoperative outcomes in gastric cancer surgery. Gastric Cancer, 2013, 16, 377-382.	2.7	34
154	Modified extended (D2) lymphadenectomy in patients with gastric cancer: Preliminary experience. Hellenike Cheirourgike Acta Chirurgica Hellenica, 2013, 85, 224-228.	0.1	0
155	ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2013, 72, 159-165.	1.1	38
156	A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemotherapy and Pharmacology, 2013, 71, 789-797.	1.1	57
158	Surgical Considerations in the Treatment of Gastric Cancer. Gastroenterology Clinics of North America, 2013, 42, 337-357.	1.0	18
159	Systematic review of laparoscopy-assisted versus open gastrectomy for advanced gastric cancer. Journal of Zhejiang University: Science B, 2013, 14, 468-478.	1.3	8
161	Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. The Cochrane Library, 2013, , CD008415.	1.5	39
162	Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer, 2013, 16, 233-238.	2.7	20
163	Radiology-guided percutaneous or endoscopic drainage: When a "mini-invasive―gesture can treat the complications of a "maxi-invasive―surgery. Journal of Visceral Surgery, 2013, 150, S1-S2.	0.4	0
164	Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. Journal of the American College of Surgeons, 2013, 217, 347-357e1.	0.2	42
165	Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e535-e547.	5.1	418
166	Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Critical Reviews in Oncology/Hematology, 2013, 88, 416-426.	2.0	39
167	Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. British Journal of Surgery, 2013, 101, 23-31.	0.1	243
168	Should we remove splenic hilus lymph nodes for esophagogastric junction adenocarcinoma?. Gastric Cancer, 2013, 16, 454-456.	2.7	2

#	ARTICLE	IF	CITATIONS
169	Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer. World Journal of Surgical Oncology, 2013, 11, 182.	0.8	62
170	Poor Prognosis of Advanced Gastric Cancer with Metastatic Suprapancreatic Lymph Nodes. Annals of Surgical Oncology, 2013, 20, 2290-2295.	0.7	21
171	Prognostic Impact of Lymph Node Retrieval and Ratio in Gastric Cancer: a U.S. Single Center Experience. Journal of Gastrointestinal Surgery, 2013, 17, 2059-2066.	0.9	21
172	Quality of Care Indicators for the Surgical Treatment of Gastric Cancer: A Systematic Review. Annals of Surgical Oncology, 2013, 20, 381-398.	0.7	28
173	The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. Journal of Surgical Oncology, 2013, 107, 641-645.	0.8	20
174	Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi57-vi63.	0.6	250
175	The diagnosis and management of gastric cancer. BMJ, The, 2013, 347, f6367-f6367.	3.0	122
176	Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 286-294.	1.3	181
177	Chemoradiation Therapy. Surgical Oncology Clinics of North America, 2013, 22, 511-524.	0.6	13
178	Risk factors for early postoperative morbidity and mortality in patients underwent radical surgery for gastric carcinoma: A single center experience. International Journal of Surgery, 2013, 11, 1103-1109.	1.1	6
179	Prognostic significance of the number of examined lymph nodes in node-negative gastric adenocarcinoma. European Journal of Surgical Oncology, 2013, 39, 1287-1293.	0.5	34
180	Multidisciplinary Management ofÂGastric Cancer. Surgical Oncology Clinics of North America, 2013, 22, 247-264.	0.6	11
181	Radical gastrectomy with para-aortic lymphadenectomy for carcinoma? The controversy continues. Commentary on Risk Factors for Metastasis to Para-Aortic Lymph Nodes in Gastric Cancer: A Single Institution Study in China. Journal of Surgical Research. Journal of Surgical Research, 2013, 185, e11-e13.	0.8	1
182	Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1721-1734.	1.2	38
183	Three decades of clinical-pathological trends in gastric cancer: Prospective data from a Portuguese hospital. International Journal of Surgery, 2013, 11, 472-476.	1.1	9
184	Morbidity and mortality after laparoscopic gastrectomy for advanced gastric cancer: results of a phase II clinical trial. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 2877-2885.	1.3	43
186	Tissue engineering and regenerative medicine as applied to the gastrointestinal tract. Current Opinion in Biotechnology, 2013, 24, 909-915.	3.3	25
188	Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: A metaâ€analysis. Journal of Surgical Oncology, 2013, 107, 807-814.	0.8	71

#	ARTICLE	IF	CITATIONS
189	Conditional Probability of Survival Nomogram for 1-, 2-, and 3-Year Survivors After an RO Resection for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 1623-1630.	0.7	60
190	Laser Microdissection and Two-Dimensional Difference Gel Electrophoresis Reveal the Role of a Novel Macrophage-Capping Protein in Lymph Node Metastasis in Gastric Cancer. Journal of Proteome Research, 2013, 12, 3780-3791.	1.8	32
191	Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1309-1314.	1.1	43
192	Poor Survival Rate in Patients with Postoperative Intra-Abdominal Infectious Complications Following Curative Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 1575-1583.	0.7	278
193	Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer ( <i>Br J) Tj ETQq0 0 0</i>	rgBT <sub>.1</sub> /Ove	rlock 10 Tf 50
194	A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2013, 72, 815-823.	1.1	48
195	Oncologic specimen from laparoscopic assisted gastrectomy for gastric adenocarcinoma is comparable to D1-open surgery: the experience of a Canadian centre. Canadian Journal of Surgery, 2013, 56, 249-255.	0.5	6
196	Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Therapeutic Advances in Medical Oncology, 2013, 5, 143-151.	1.4	68
197	(Neo)-Adjuvant Chemo(-Radio) Therapy for Adenocarcinomas of the Gastroesophageal Junction and the Stomach in the West. Digestive Surgery, 2013, 30, 112-118.	0.6	14
198	Risk factors for No. 12p and No. 12b lymph node metastases in advanced gastric cancer in China. Upsala Journal of Medical Sciences, 2013, 118, 9-15.	0.4	7
199	Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation. Oncologist, 2013, 18, 1013-1021.	1.9	38
200	Advanced gastric cancer: is chemotherapy needed after surgery?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 673-675.	1.4	4
201	Sentinel Node Mapping for Gastric Cancer: A Prospective Multicenter Trial in Japan. Journal of Clinical Oncology, 2013, 31, 3704-3710.	0.8	290
202	Laparoscopic Gastrectomy for Gastric Cancer with Simultaneous Organ Resection. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2013, 23, 861-865.	0.5	7
203	Laparoscopy: A Procedure no less than Laparotomy for Lymph Node Dissection in Total Gastrectomy for Gastric Carcinoma. World Journal of Laparoscopic Surgery, 2013, 6, 111-115.	0.2	0
204	Overview of Adjuvant and Neoadjuvant Therapy for Resectable Gastric Cancer in the East. Digestive Surgery, 2013, 30, 119-129.	0.6	49
205	Changes in treatment patterns and their influence on long-term survival in patients with stages I-III gastric cancer in The Netherlands. International Journal of Cancer, 2013, 133, 1859-1866.	2.3	42
206	Actualización del diagnóstico y tratamiento del cáncer gástrico. Revista Médica ClÃnica Las Condes, 2013, 24, 627-636.	0.2	1

#	Article	IF	Citations
207	Comparison of Short-Term Clinical Outcomes Between Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Meta-analysis of 2495 Patients. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2013, 23, 965-976.	0.5	33
208	Gastric cancer: past accomplishments, present approaches and future aspirations. Clinical Practice (London, England), 2013, 10, 47-77.	0.1	0
209	Improving the outcome of colorectal cancer: the European Registration of Cancer Care (EURECCA) project. Colorectal Cancer, 2013, 2, 371-376.	0.8	3
210	Minimalinvasive Chirurgie bei Malignomen des Gastrointestinaltrakts: Magen - Kontra-Position. Visceral Medicine, 2013, 29, 362-367.	0.5	1
211	Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment. World Journal of Surgical Oncology, 2013, 11, 287.	0.8	11
212	Gastric Cancer, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 531-546.	2.3	422
213	Laparoscopic Surgery for Advanced Gastric Cancer: Current Status and Future Perspectives. Journal of Gastric Cancer, 2013, 13, 19.	0.9	77
214	Totally Laparoscopic Distal Gastrectomy with D <sub>2</sub> Lymphadenectomy and Billroth II Gastrojejunostomy for Gastric Cancer: Short- and Medium-term Results of 139 Consecutive Cases from a Single Institution. International Journal of Medical Sciences, 2013, 10, 1462-1470.	1.1	37
215	Evaluation of FLT-PET/CT usefulness in diagnosis and qualification for surgical treatment of gastric cancer. Wspolczesna Onkologia, 2013, 2, 165-170.	0.7	6
216	The influence of advanced age on the morbi-mortality of gastric cancer after curative surgery. Revista Espanola De Enfermedades Digestivas, 2013, 105, 194-200.	0.1	2
217	Risk Factors of Postoperative Pancreatic Fistula in Curative Gastric Cancer Surgery. Journal of Gastric Cancer, 2013, 13, 179.	0.9	29
218	Laparoscopy Assisted versus Open Distal Gastrectomy with D2 Lymph Node Dissection for Advanced Gastric Cancer: Design and Rationale of a Phase II Randomized Controlled Multicenter Trial (COACT) Tj ETQq1 1	0.78 <b>4</b> 314	rg <b>B3</b> /Over
219	Robotic versus Open Gastrectomy for Gastric Cancer: A Meta-Analysis. PLoS ONE, 2013, 8, e81946.	1.1	42
220	Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices. Gut and Liver, 2013, 7, 385-395.	1.4	57
221	Lymph Node Ratio as a Predictor of Survival in Gastric Carcinoma. American Surgeon, 2013, 79, 284-289.	0.4	15
222	What is the Role of Nodal Ratio as a Prognostic Factor for Gastric Cancer Nowadays? Comparison with New TNM Staging System and Analysis According to the Number of Resected Nodes. American Surgeon, 2013, 79, 483-491.	0.4	11
223	Clinical significance of lymph node metastasis in gastric cancer. World Journal of Gastroenterology, 2014, 20, 3967.	1.4	144
224	Laparoscopic versus Open Total Gastrectomy for Gastric Cancer: An Updated Meta-Analysis. PLoS ONE, 2014, 9, e88753.	1.1	61

#	ARTICLE	IF	Citations
225	Laparoscopic Spleen-Preserving Splenic Hilar Lymphadenectomy Performed by Following the Perigastric Fascias and the Intrafascial Space for Advanced Upper-Third Gastric Cancer. PLoS ONE, 2014, 9, e90345.	1.1	12
226	Metastasis, Risk Factors and Prognostic Significance of Splenic Hilar Lymph Nodes in Gastric Adenocarcinoma. PLoS ONE, 2014, 9, e99650.	1.1	18
227	Adjuvant therapy for gastric cancer: Current and future directions. World Journal of Gastroenterology, 2014, 20, 13718.	1.4	38
228	Treatment of gastric cancer. World Journal of Gastroenterology, 2014, 20, 1635.	1.4	508
229	Length of negative resection margin does not affect local recurrence and survival in the patients with gastric cancer. World Journal of Gastroenterology, 2014, 20, 10518.	1.4	26
230	A phase II trial of post-operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy. Oncology Letters, 2014, 8, 1844-1848.	0.8	3
231	The Assessment of the Oncological Safety Margin of Insufficient Lymph Node Dissection in pT2 (pm) Gastric Cancer. Yonsei Medical Journal, 2014, 55, 61.	0.9	3
232	Can Perioperative Chemotherapy for Advanced Gastric Cancer Be Recommended on the Basis of Current Research? A Critical Analysis. Journal of Gastric Cancer, 2014, 14, 39.	0.9	12
234	MicroRNAs as potential biomarkers for gastric cancer. World Journal of Gastroenterology, 2014, 20, 12007.	1.4	90
235	Subtotal gastrectomy for gastric cancer. World Journal of Gastroenterology, 2014, 20, 13667.	1.4	44
236	Laparoscopic spleen-preserving splenic hilar lymphadenectomy in 108 consecutive patients with upper gastric cancer. World Journal of Gastroenterology, 2014, 20, 11376.	1.4	20
237	How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer. Oncologist, 2014, 19, 1046-1055.	1.9	20
238	Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer, 2014, 14, 984.	1.1	50
239	Trends and results in treatment of gastric cancer over last two decades at single East European centre: a cohort study. BMC Surgery, 2014, 14, 98.	0.6	14
240	Is Laparoscopic Surgery the Standard of Care for GI Luminal Cancer?. Indian Journal of Surgery, 2014, 76, 444-452.	0.2	2
242	Controversies in management of gastric cancer. Current Medicine Research and Practice, 2014, 4, 263-273.	0.1	0
243	Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Annals of Oncology, 2014, 25, 1485-1492.	0.6	43
244	The Prognostic Value of Lymph Nodes Dissection Number on Survival of Patients with Lymph Node-Negative Gastric Cancer. Gastroenterology Research and Practice, 2014, 2014, 1-6.	0.7	27

#	Article	IF	CITATIONS
245	Enhanced recovery after surgery in laparoscopic gastric cancer surgery: Many questions, few answers. Journal of Minimal Access Surgery, 2014, 10, 105.	0.4	5
246	Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells. Oncology Letters, 2014, 8, 1603-1607.	0.8	18
248	Undervalued Criteria in the Evaluation of Multimodal Trials for Upper GI Cancers. Cancer Investigation, 2014, 32, 497-506.	0.6	2
249	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Annals of Oncology, 2014, 25, 1373-1378.	0.6	84
250	Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery. British Journal of Surgery, 2014, 101, 1712-1720.	0.1	28
251	Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. British Journal of Surgery, 2014, 101, 595-604.	0.1	66
252	Trends in the use of evidenceâ€based therapy for resectable gastric cancer. Journal of Surgical Oncology, 2014, 110, 285-290.	0.8	28
253	Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the <scp>N</scp> ational <scp>C</scp> ancer <scp>D</scp> ata <scp>B</scp> ase. Cancer, 2014, 120, 2855-2865.	2.0	54
254	Robot-assisted laparoscopic (RAL) surgery for gastric cancer. International Journal of Medical Robotics and Computer Assisted Surgery, 2014, 10, 257-262.	1.2	11
255	Clinical audit of gastrectomy for gastric adenocarcinoma: Results of a single institution. Surgical Practice, 2014, 18, 128-135.	0.1	0
258	Lymphadenectomy for Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2014, 259, 213-214.	2.1	9
260	Robot assisted laparoscopic (RAL) gastrectomy: case series and a review of the literature. Turkish Journal of Surgery, 2014, 29, 187-191.	1.0	3
261	Prognostic significance of splenectomy for patients with gastric adenocarcinoma undergoing total gastrectomy: A retrospective cohort study. International Journal of Surgery, 2014, 12, 557-565.	1.1	21
262	Gastric cancerâ€: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2014, 110, 189-194.	0.3	27
263	Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery, 2014, 155, 408-416.	1.0	43
264	Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surgery Today, 2014, 44, 11-21.	0.7	59
265	N stages of the seventh edition of TNM Classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy. Tumor Biology, 2014, 35, 3269-3281.	0.8	14
267	Prognostic Significance of Complications after Curative Surgery for Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 891-898.	0.7	180

#	Article	IF	CITATIONS
268	Laparoscopic resections and ENCODE-guided genomics to advance surgery and oncology. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 2244-2246.	1.3	2
269	Anatomic Extent of Metastatic Lymph Nodes: Still Important for Gastric Cancer Prognosis. Annals of Surgical Oncology, 2014, 21, 899-907.	0.7	20
270	Benefit of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis. Tumor Biology, 2014, 35, 4957-4966.	0.8	9
271	Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04 Radiation Oncology, 2014, 9, 9.	1.2	13
272	Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 281-285.	1.1	19
274	Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. European Journal of Cancer, 2014, 50, 1330-1344.	1.3	556
275	Unmet needs and challenges in gastric cancer: The way forward. Cancer Treatment Reviews, 2014, 40, 692-700.	3.4	156
276	Laparoscopic versus open gastrectomy for gastric cancer: Long-term oncologic results. Surgery, 2014, 155, 154-164.	1.0	46
278	Distal Gastrectomy with D2 Nodal Dissection. , 2014, , 343-351.		0
279	Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1389-1396.	5.1	849
280	Oncology Scanâ€"Novel Treatment Strategies for Gastrointestinal Cancers. International Journal of Radiation Oncology Biology Physics, 2014, 89, 699-703.	0.4	4
281	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530.	0.8	36
282	Surgical strategy for gastric cancer patients with liver cirrhosis: A retrospective cohort study. International Journal of Surgery, 2014, 12, 810-814.	1.1	18
283	Role of (Chemo)-Radiotherapy in Resectable Gastric Cancer. Clinical Oncology, 2014, 26, 541-550.	0.6	12
284	Outcomes of surgical treatment for gastric cancer patients: 11-year experience of a Chinese high-volume hospital. Medical Oncology, 2014, 31, 150.	1.2	30
285	Trends in clinical features, postoperative outcomes, and long-term survival for gastric cancer: a Western experience with 1,278 patients over 30Âyears. World Journal of Surgical Oncology, 2014, 12, 217.	0.8	27
287	Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 2340-2346.	0.7	35
288	Perioperative Risk Assessment for Gastrectomy by Surgical Apgar Score. Annals of Surgical Oncology, 2014, 21, 2601-2607.	0.7	54

#	Article	IF	CITATIONS
289	Morbidity and Mortality Associated with Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 3008-3014.	0.7	191
290	Status and prognosis of lymph node metastasis in patients with cardia cancer – A systematic review. Surgical Oncology, 2014, 23, 140-146.	0.8	44
291	Short-term surgical and long-term survival outcomes after laparoscopic distal gastrectomy with D2 lymphadenectomy for gastric cancer. BMC Gastroenterology, 2014, 14, 41.	0.8	33
292	Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surgery, 2014, 14, 29.	0.6	17
293	Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. European Journal of Surgical Oncology, 2014, 40, 584-591.	0.5	162
294	Comparison of the staging of regional lymph nodes using the sixth and seventh editions of the tumor-node-metastasis (TNM) classification system for the evaluation of overall survival in gastric cancer patients: Findings of a case-control analysis involving a single institution in China. Surgery, 2014. 156. 64-74.	1.0	37
295	Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiotherapy and Oncology, 2014, 112, 284-288.	0.3	40
296	Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer. Journal of Surgical Research, 2014, 192, 90-97.	0.8	17
297	Update on treatment of gastric cancer. Journal of the Chinese Medical Association, 2014, 77, 345-353.	0.6	45
298	Improving the outcomes in gastric cancer surgery. World Journal of Gastroenterology, 2014, 20, 13692.	1.4	67
299	External Validation of an Eastern Asian Nomogram for Survival Prediction After Gastric Cancer Surgery in a European Patient Cohort. Medicine (United States), 2015, 94, e2406.	0.4	5
300	Seom guidelines for the treatment of gastric cancer 2015. Clinical and Translational Oncology, 2015, 17, 996-1004.	1.2	25
301	Effect of Perioperative Transfusion on Survival and Morbidity for Gastric Cancer Patients with Gastrectomy. Journal of the American College of Surgeons, 2015, 221, 995-996.	0.2	3
302	Current status of randomized controlled trials for laparoscopic gastric surgery for gastric cancer in <scp>K</scp> orea. Asian Journal of Endoscopic Surgery, 2015, 8, 130-138.	0.4	8
303	Comparison of Lymphatic System Staging Classifications in Patients with Gastric Cancer. Polski Przeglad Chirurgiczny, 2015, 87, 551-7.	0.2	2
304	GI Surgery Annual. GI Surgery Annual, 2015, , .	0.0	0
305	Prognostic significance of distal subtotal gastrectomy with standard D2 and extended D2 lymphadenectomy for locally advanced gastric cancer. Scientific Reports, 2015, 5, 17273.	1.6	8
306	Unusual complication of multiple splenic abscesses arising from a feeding jejunostomy tube subsequent to total gastrectomy: A case report and literature review. Oncology Letters, 2015, 9, 2398-2400.	0.8	1

#	Article	IF	Citations
307	Key New Studies in Gastric and Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 475-481.	0.4	1
308	Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. British Journal of Surgery, 2015, 102, 1388-1393.	0.1	65
309	Difficulty of predicting the presence of lymph node metastases in patients with clinical early stage gastric cancer: a case control study. BMC Cancer, 2015, 15, 943.	1.1	22
310	Analysis of surgery for incurable gastric cancer. World Journal of Surgical Oncology, 2015, 13, 339.	0.8	3
311	Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction. Journal of Clinical Gastroenterology, 2015, 49, 387-394.	1.1	37
312	Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 282-287.	0.7	17
313	Collateral thermal damage to the pancreas by ultrasonic instruments during lymph node dissection in laparoscopic gastrectomy. Asian Journal of Endoscopic Surgery, 2015, 8, 281-288.	0.4	29
314	The Value of Palliative Gastrectomy for Gastric Cancer Patients With Intraoperatively Proven Peritoneal Seeding. Medicine (United States), 2015, 94, e1051.	0.4	25
315	Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach. Annals of Surgery, 2015, 262, 1092-1101.	2.1	192
316	Extent of lymph node dissection for adenocarcinoma of the stomach. The Cochrane Library, 2015, 2015, CD001964.	1.5	66
317	Association of <i> PSCA </i> > rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease. International Journal of Cancer, 2015, 1362-1373.	2.3	39
318	Assessing the feasibility of full robotic interaortocaval nodal dissection for locally advanced gastric cancer. International Journal of Medical Robotics and Computer Assisted Surgery, 2015, 11, 218-222.	1.2	5
319	S-1 combined with cisplatin versus cisplatin alone for the treatment of advanced gastric cancer. Anti-Cancer Drugs, 2015, 26, 774-778.	0.7	6
320	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	2.1	83
321	Risk Model for Distal Gastrectomy When Treating Gastric Cancer on the Basis of Data From 33,917 Japanese Patients Collected Using a Nationwide Web-based Data Entry System. Annals of Surgery, 2015, 262, 295-303.	2.1	129
322	Laparoscopic Total Gastrectomy in the Western Patient Population. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2015, 25, 455-461.	0.4	2
323	Multimodal treatment of gastric cancer in the west: Where are we going?. World Journal of Gastroenterology, 2015, 21, 7954.	1.4	59
324	Perioperative treatments for resectable gastric cancer. Journal of the Korean Medical Association, 2015, 58, 201.	0.1	3

#	Article	IF	CITATIONS
325	Time-Dependent Effects of Prognostic Factors in Advanced Gastric Cancer Patients. Journal of Gastric Cancer, 2015, 15, 238.	0.9	1
326	Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World Journal of Gastroenterology, 2015, 21, 11428.	1.4	226
327	Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Medical Journal, 2015, 56, 1177.	0.9	49
328	Survival of Proper Hepatic Artery Lymph Node Metastasis in Patients with Gastric Cancer: Implications for D2 Lymphadenectomy. PLoS ONE, 2015, 10, e0118953.	1.1	11
329	Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	3
330	MALDI-TOF Mass Array Analysis of <i>Nell-1 &lt; /i&gt;Promoter Methylation Patterns in Human Gastric Cancer. BioMed Research International, 2015, 2015, 1-8.</i>	0.9	7
331	Risk Factors and Prognostic Significance of Retropancreatic Lymph Nodes in Gastric Adenocarcinoma. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	3
332	Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus. Gastroenterology Research and Practice, 2015, 2015, 1-4.	0.7	8
333	Prognostic Value of Metastatic No.8p LNs in Patients with Gastric Cancer. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	4
334	Neoadjuvant or adjuvant therapy for gastric cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 102.	0.8	31
335	Short-Term Outcomes of Laparoscopic Total Gastrectomy Performed by a Single Surgeon Experienced in Open Gastrectomy: Review of Initial Experience. Journal of Gastric Cancer, 2015, 15, 159.	0.9	18
336	Effect of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor on Disease Activity in Patients With Rheumatoid Arthritis. Medicine (United States), 2015, 94, e572.	0.4	19
337	N3 Subclassification Incorporated into the Final Pathologic Staging of Gastric Cancer. Medicine (United States), 2015, 94, e575.	0.4	14
338	Impact of <i>CYP2D6</i> Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients. Genetic Testing and Molecular Biomarkers, 2015, 19, 248-252.	0.3	9
339	Resected gastric cancer with D2 dissection: advances in adjuvant chemoradiotherapy and radiotherapy techniques. Expert Review of Anticancer Therapy, 2015, 15, 703-713.	1.1	4
340	The Role of the Cancer Center When Using Lymph Node Count as a Quality Measure for Gastric Cancer Surgery. JAMA Surgery, 2015, 150, 37.	2.2	64
341	The positive impact of surgeon specialization on survival for gastric cancer patients after surgery with curative intent. Gastric Cancer, 2015, 18, 859-867.	2.7	18
342	Robotic surgery for gastric cancer. Gastric Cancer, 2015, 18, 449-457.	2.7	46

#	Article	IF	Citations
343	Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer, 2015, 15, 355.	1.1	87
344	The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China. BMC Cancer, 2015, 15, 370.	1.1	44
345	Should the Results of the New EPOC Trial Change Practice in the Management of Patients With Resectable Metastatic Colorectal Cancer Confined to the Liver?. Journal of Clinical Oncology, 2015, 33, 241-243.	0.8	32
347	The Current Status and Development of Lymph Node Dissection for Gastric Cancer., 2015, , 7-12.		0
348	Lymph Node Count as a Quality Measure for Gastric Cancer Surgery. JAMA Surgery, 2015, 150, 595.	2.2	2
349	Overall Survival Is Impacted by Birthplace and Not Extent of Surgery in Asian Americans with Resectable Gastric Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 1966-1973.	0.9	14
350	Radix ranunculus temate saponins induces apoptosis via the death receptor and mitochondrial pathways in SGC-7901 cells. Molecular and Cellular Toxicology, 2015, 11, 449-455.	0.8	1
351	Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (United) Tj ETQq1 1	0.784314	· rgBT /Overlo
352	Targeting effect of PEGylated liposomes modified with the Arg-Gly-Asp sequence on gastric cancer. Oncology Reports, 2015, 34, 1825-1834.	1,2	25
353	Ultrasonic dissection versus conventional electrocautery during gastrectomy for gastric cancer: A meta-analysis of randomized controlled trials. European Journal of Surgical Oncology, 2015, 41, 527-533.	0.5	8
354	Clinical significance of skip lymph node metastasis in gastric cancer patients. European Journal of Surgical Oncology, 2015, 41, 339-345.	0.5	25
355	Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery, 2015, 157, 285-296.	1.0	49
356	Current Status of Management of Malignant Disease: Current Management of Gastric Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 782-788.	0.9	27
357	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. Journal of Clinical Oncology, 2015, 33, 3130-3136.	0.8	370
358	Short- and long-term outcomes of LigaSure versus conventional surgery for curative gastric cancer resection: a matched pair analysis. Gastric Cancer, 2015, 18, 843-849.	2.7	10
359	Gastric cancer recurrence after resection and adjuvant chemoradiation. Journal of Radiation Oncology, 2015, 4, 79-85.	0.7	1
360	Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?. Current Oncology Reports, 2015, 17, 18.	1.8	3
361	Comparison of Gastric Cancer Survival Between Caucasian and Asian Patients Treated in the United States: Results from the Surveillance Epidemiology and End Results (SEER) Database. Annals of Surgical Oncology, 2015, 22, 2965-2971.	0.7	86

#	Article	IF	CITATIONS
362	Functional Outcomes and Quality of Life After Proximal Gastrectomy with Esophagogastrostomy Using a Narrow Gastric Conduit. Annals of Surgical Oncology, 2015, 22, 772-779.	0.7	46
363	Superiority of the Ratio Between Negative and Positive Lymph Nodes for Predicting the Prognosis for Patients With Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 1258-1266.	0.7	29
364	Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer?. European Journal of Surgical Oncology, 2015, 41, 779-786.	0.5	42
365	Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer. Oncology, 2015, 88, 281-288.	0.9	3
366	Adjuvant and Neoadjuvant Treatment: Standard Treatment and Clinical Trials in the East. , 2015, , 303-306.		0
367	Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 291-299.	0.2	73
368	Does lymph node ratio affect prognosis in gastroesophageal cancer?. American Journal of Surgery, 2015, 210, 443-450.	0.9	17
369	Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. European Journal of Surgical Oncology, 2015, 41, 534-540.	0.5	40
370	Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients. Surgical Oncology, 2015, 24, 84-88.	0.8	51
371	Controversies in the Treatment of Local and Locally Advanced Gastric and Esophageal Cancers. Journal of Clinical Oncology, 2015, 33, 1754-1759.	0.8	77
372	Predictive factors for survival and recurrence rate in patients with node-negative gastric cancer—a European single-centre experience. Langenbeck's Archives of Surgery, 2015, 400, 27-35.	0.8	20
373	Robotic general surgery: current practice, evidence, and perspective. Langenbeck's Archives of Surgery, 2015, 400, 283-292.	0.8	41
374	Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 3251-3260.	1.3	97
375	Chemoradiation for gastric cancer: controversies, updates and novel techniques. British Journal of Radiology, 2015, 88, 20150027.	1.0	3
376	Incorporating Surgical Quality into the AJCC 7th Edition Improves Staging Accuracy in Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 11-16.	0.7	17
377	Comparison of Reduced Port Totally Laparoscopic Distal Gastrectomy (Duet TLDG) and Conventional Laparoscopic-Assisted Distal Gastrectomy. Annals of Surgical Oncology, 2015, 22, 2567-2572.	0.7	52
378	Feasibility of Gastrectomy with Standard Lymphadenectomy for Patients Over 85ÂYears Old with Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 3962-3969.	0.7	22
379	Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer. Digestive Surgery, 2015, 32, 229-237.	0.6	25

#	Article	IF	CITATIONS
380	External Validation of a Score Predictive of Recurrence after Radical Surgery for Non-Cardia Gastric Cancer: Results of a Follow-Up Study. Journal of the American College of Surgeons, 2015, 221, 280-290.	0.2	24
381	Laparoscopic Gastrectomy for Gastric Cancer. , 2015, , .		19
382	Lymphadenectomy extent and survival of patients with gastric carcinoma: A systematic review and meta-analysis of time-to-event data from randomized trials. Cancer Treatment Reviews, 2015, 41, 448-454.	3.4	33
383	Long-term Survival Outcomes of Laparoscopic Versus Open Gastrectomy for Gastric Cancer. Medicine (United States), 2015, 94, e454.	0.4	42
384	Necessity of Harvesting At Least 25 Lymph Nodes in Patients With Stage N2–N3 Resectable Gastric Cancer. Medicine (United States), 2015, 94, e620.	0.4	29
386	Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncology, The, 2015, 16, 1193-1224.	5.1	442
387	Updated evidence on adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1549-1560.	1.4	47
388	Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. Annals of Surgical Oncology, 2015, 22, 863-872.	0.7	15
389	Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. Surgery, 2015, 158, 1573-1580.	1.0	53
390	Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 840-847.	0.7	32
391	Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surgery, 2015, 15, 66.	0.6	21
392	Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy. Future Oncology, 2015, 11, 2247-2249.	1.1	2
393	Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options?. Journal of Clinical Oncology, 2015, 33, 3085-3091.	0.8	12
394	Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study. Acta Oncol $\tilde{A}^3$ gica, 2015, 54, 1754-1762.	0.8	15
396	Screening and Early Detection of Gastric Cancer. Surgical Clinics of North America, 2015, 95, 1053-1066.	0.5	54
397	Optimal management of resectable gastric adenocarcinoma. Expert Review of Anticancer Therapy, 2015, 15, 931-941.	1.1	2
398	Centralization of the management of sarcoma? Probably yes, but not only for surgical practice. Journal of Visceral Surgery, 2015, 152, 207-209.	0.4	1
399	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. Radiotherapy and Oncology, 2015, 117, 171-177.	0.3	31

#	Article	IF	CITATIONS
400	A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer. Medical Oncology, 2015, 32, 241.	1.2	47
401	Global cancer surgery: The Lancet Oncology review. European Journal of Surgical Oncology, 2015, 41, 1559-1561.	0.5	17
402	Time trends of clinicopathologic features and surgical treatment for gastric cancer: Results from 2 high-volume institutions in southern China. Surgery, 2015, 158, 1590-1597.	1.0	25
403	Management of gastric cancer: East vs west. Current Problems in Cancer, 2015, 39, 315-341.	1.0	7
404	Clinical trials of interventional oncologyâ€"moving from efficacy to outcomes. Nature Reviews Clinical Oncology, 2015, 12, 93-104.	12.5	18
405	Upper lesser curvature skeletonization in radical distal gastrectomy. Journal of Surgical Research, 2015, 193, 168-175.	0.8	6
406	Personalized Surgery for Gastric Adenocarcinoma: A Meta-analysis of D1 versus D2 Lymphadenectomy. Annals of Surgical Oncology, 2015, 22, 1820-1827.	0.7	37
408	Laparoscopic Distal, Subtotal Gastrectomy for Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 369-374.	0.9	9
409	Quality of D2 lymphadenectomy for advanced gastric cancer: is laparoscopic-assisted distal gastrectomy as effective as open distal gastrectomy?. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 1537-1544.	1.3	19
411	The evolution of cancer surgery and future perspectives. Nature Reviews Clinical Oncology, 2015, 12, 115-124.	12.5	226
412	Total Gastrectomy for Gastric Cancer: An Analysis of Postoperative and Long-Term Outcomes Through Time. Annals of Surgical Oncology, 2015, 22, 750-757.	0.7	15
413	International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer, 2015, 18, 550-563.	2.7	79
414	Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 224-231.	0.7	50
415	Prognostic nutritional index is an independent prognostic factor for gastric cancer patients with peritoneal dissemination. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 570-578.	0.7	15
416	Development and external validation of a prognostic nomogram for gastric cancer using the national cancer registry. Oncotarget, 2016, 7, 35853-35864.	0.8	42
417	Short-Term Outcomes of Laparoscopic Distal Gastrectomy for Advanced Gastric Cancer. Journal of Medical Investigation, 2016, 63, 68-73.	0.2	1
418	Ongoing surgical clinical trials on minimally invasive surgery for gastric cancer: Korea. Translational Gastroenterology and Hepatology, 2016, 1, 40-40.	1.5	7
419	Quality of life: A critical outcome for all surgical treatments of gastric cancer. World Journal of Gastroenterology, 2016, 22, 1101.	1.4	47

#	Article	IF	CITATIONS
420	Laparoscopic and robot-assisted gastrectomy for gastric cancer: Current considerations. World Journal of Gastroenterology, 2016, 22, 5694.	1.4	45
421	Molecular mechanisms of peritoneal dissemination in gastric cancer. World Journal of Gastroenterology, 2016, 22, 6829.	1.4	121
422	On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 489.	0.8	6
423	The thinking to the huge disease burden of gastric cancer in China and the increasing tendency of esophagogastric junctional adenocarcinoma. Translational Gastroenterology and Hepatology, 2016, 1, 32-32.	1.5	1
424	Historical assumptions of lymphadenectomy. Translational Gastroenterology and Hepatology, 2016, 1, 90-90.	1.5	1
425	Management of postoperative complications of lymphadenectomy. Translational Gastroenterology and Hepatology, 2016, 1, 92-92.	1.5	10
426	Lymphadenectomy in gastric cancer: Contentious issues. World Journal of Gastrointestinal Surgery, 2016, 8, 294.	0.8	17
427	Worldwide practice in gastric cancer surgery. World Journal of Gastroenterology, 2016, 22, 4041.	1.4	52
428	Clinical significance of lymphadenectomy in patients with gastric cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 136.	0.8	8
429	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. Journal of Gastric Cancer, 2016, 16, 105.	0.9	34
430	Gastric cancer: Current status of lymph node dissection. World Journal of Gastroenterology, 2016, 22, 2875.	1.4	124
431	Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas. PLoS ONE, 2016, 11, e0168237.	1.1	2
432	Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States. Annals of Surgery, 2016, 263, 298-305.	2.1	25
433	Is Extended Lymphadenectomy Needed for Elderly Patients With Gastric Adenocarcinoma?. Annals of Surgical Oncology, 2016, 23, 2391-2397.	0.7	9
434	Prognostic impact of the number of retrieved lymph nodes in patients with gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1566-1571.	1.4	36
435	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 685-691.	0.8	48
436	Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7â€institution study of the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2016, 113, 750-755.	0.8	33
437	Comparing the shortâ€term outcomes of laparoscopic distal gastrectomy with <scp>D</scp> 1+ and <scp>D</scp> 2 lymph node dissection for gastric cancer. Asian Journal of Endoscopic Surgery, 2016, 9, 116-121.	0.4	4

#	Article	IF	Citations
438	Positive Lymph Node Ratio as an Indicator of Prognosis and Local Tumor Clearance in N3 Gastric Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 1565-1571.	0.9	31
439	Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study. International Journal of Hyperthermia, 2016, 32, 587-594.	1.1	13
440	Significant Role of Palliative Gastrectomy in Selective Gastric Cancer Patients with Peritoneal Dissemination: A Propensity Score Matching Analysis. Annals of Surgical Oncology, 2016, 23, 3956-3963.	0.7	19
441	The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. SpringerPlus, 2016, 5, 728.	1.2	5
442	Learning curve for gastric cancer patients with laparoscopy-assisted distal gastrectomy. Medicine (United States), 2016, 95, e4875.	0.4	20
443	Prognostic relevance of SAMSN1 expression in gastric cancer. Oncology Letters, 2016, 12, 4708-4716.	0.8	16
444	The Radical Extent of lymphadenectomy â€" D2 dissection versus complete mesocolic excision of LAparoscopic Right Colectomy for right-sided colon cancer (RELARC) trial: study protocol for a randomized controlled trial. Trials, 2016, 17, 582.	0.7	48
445	Short-term outcomes of laparoscopic D2 lymphadenectomy with complete mesogastrium excision for advanced gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 5138-5139.	1.3	27
446	The impact of age on nodal metastases and survival in gastric cancer. Journal of Surgical Research, 2016, 202, 428-435.	0.8	7
447	Differential expression profiles of long non-coding RNAs reveal potential biomarkers for identification of human gastric cancer. Oncology Reports, 2016, 35, 1529-1540.	1.2	28
448	Targeted therapy in gastric cancer. European Surgery - Acta Chirurgica Austriaca, 2016, 48, 278-284.	0.3	23
449	Surgical Oncology Manual., 2016, , .		1
450	Gastric cancer. Lancet, The, 2016, 388, 2654-2664.	6.3	1,560
451	Evolution of gastric surgery techniques and outcomes. Chinese Journal of Cancer, 2016, 35, 69.	4.9	13
452	An update on gastric cancer. Current Problems in Surgery, 2016, 53, 449-490.	0.6	32
453	D2â€resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Medicine, 2016, 5, 2773-2780.	1.3	11
454	Long-Term Survival in Patients with Postoperative Intra-Abdominal Infectious Complications After Curative Gastrectomy for Gastric Cancer: A Propensity Score Matching Analysis. Annals of Surgical Oncology, 2016, 23, 809-816.	0.7	47
455	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v38-v49.	0.6	1,212

#	Article	IF	Citations
456	Who may benefit from robotic gastrectomy?: A subgroup analysis of multicenter prospective comparative study data on robotic versus laparoscopic gastrectomy. European Journal of Surgical Oncology, 2016, 42, 1944-1949.	0.5	51
457	Technical Details of an Anterior Approach to the Superior Mesenteric Artery During Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2016, 20, 1769-1777.	0.9	25
458	Focus on research: Nodal dissection for gastric cancer – A dilemma worthy of King Solomon!. European Journal of Surgical Oncology, 2016, 42, 1623-1624.	0.5	9
459	The current state of stomach cancer surgery in the world. Japanese Journal of Clinical Oncology, 2016, 46, 1062-1071.	0.6	13
460	Role of omentectomy as part of radical surgery for gastric cancer. British Journal of Surgery, 2016, 103, 1497-1503.	0.1	50
461	Survival outcomes of geriatric patients with clinically resectable gastric cancer: to operate or not. Journal of Surgical Research, 2016, 206, 481-489.	0.8	7
462	Evaluation of the recurrence pattern of gastric cancer after laparoscopic gastrectomy with D2 lymphadenectomy. SpringerPlus, 2016, 5, 821.	1.2	7
463	Reply to the Letter. Annals of Surgery, 2016, 264, e5-e6.	2.1	4
464	Adjuvant chemoradiotherapy combined with cisplatin, 5-fluorouracil and folinic acid for locally advanced gastric cancer. Journal of Oncological Science, 2016, 2, 12-15.	0.1	3
465	Postoperative chemoradiotherapy versus chemotherapy for RO resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World Journal of Surgical Oncology, 2016, 14, 209.	0.8	31
466	Gastric Cancer Management â€" East vs. West?. , 2016, , 133-152.		0
468	Comparison of different methods of splenic hilar lymph node dissection for advanced upper- and/or middle-third gastric cancer. BMC Cancer, 2016, 16, 765.	1.1	11
469	Different survival outcomes after curative RO-resection for Eastern Asian and European gastric cancer. Medicine (United States), 2016, 95, e4261.	0.4	7
470	Multimodality Therapy of Localized Gastric Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1321-1327.	2.3	29
471	DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases. Medicine (United States), 2016, 95, e3236.	0.4	10
472	Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome. Medicine (United States), 2016, 95, e4322.	0.4	18
473	Initial report of nearâ€infrared fluorescence imaging as an intraoperative adjunct for lymph node harvesting during robotâ€assisted laparoscopic gastrectomy. Journal of Surgical Oncology, 2016, 113, 768-770.	0.8	43
474	Gastric cancer: <scp>A</scp> ustralian outcomes of multiâ€modality treatment with curative intent. ANZ Journal of Surgery, 2016, 86, 386-390.	0.3	3

#	Article	IF	CITATIONS
475	Clinical study of harvesting lymph nodes with carbon nanoparticles in advanced gastric cancer: a prospective randomized trial. World Journal of Surgical Oncology, 2016, 14, 88.	0.8	52
476	Impact of Abdominal Shape on Short-Term Surgical Outcome of Laparoscopy-Assisted Distal Gastrectomy for Gastric Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 1091-1097.	0.9	7
477	Technical aspects and short- and long-term outcomes of totally laparoscopic total gastrectomy for advanced gastric cancer: a single-institution retrospective study. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4632-4639.	1.3	43
478	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Journal of Clinical Oncology, 2016, 34, 2721-2727.	0.8	214
479	Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4353-4362.	1.3	20
481	Extended lymphadenectomy in elderly and/or highly co-morbid gastric cancer patients: A retrospective multicenter study. European Journal of Surgical Oncology, 2016, 42, 1881-1889.	0.5	36
482	Significance of lymphadenectomy with splenectomy in radical surgery for advanced (pT3/pT4) remnant gastric cancer. Surgery, 2016, 159, 1082-1089.	1.0	9
483	Practical intraoperative pathologic evaluation of sentinel lymph nodes during sentinel node navigation surgery in gastric cancer patients $\hat{a}$ Proposal of the pathologic protocol for the upcoming SENORITA trial. Surgical Oncology, 2016, 25, 139-146.	0.8	19
484	Laparoscopic gastrectomy versus open gastrectomy for elderly patients with gastric cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2016, 14, 90.	0.8	46
485	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer, 2016, 16, 112.	1.1	17
487	Postoperative Morbidity and Mortality Following D2 Gastrectomy-an Audit of 456 Cases. Indian Journal of Surgical Oncology, 2016, 7, 4-10.	0.3	7
488	Reply to F.C.M. Cananzi et al. Journal of Clinical Oncology, 2016, 34, 1422-1423.	0.8	0
489	Optimal settings and accuracy of indocyanine green fluorescence imaging for sentinel node biopsy in early gastric cancer. Oncology Letters, 2016, 11, 4055-4062.	0.8	59
490	Tissue Engineering and Regenerative Medicine. , 2016, , 65-74.		0
491	Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer, 2016, 19, 255-263.	2.7	70
492	Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer, 2016, 19, 226-233.	2.7	32
493	C-reactive protein on postoperative day 3 as a predictor of infectious complications following gastric cancer resection. Gastric Cancer, 2016, 19, 293-301.	2.7	43
494	The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer, 2016, 19, 479-489.	2.7	22

#	Article	IF	CITATIONS
495	Subtotal gastrectomy with conventional D2 lymphadenectomy for carcinoma of the distal gastric portion: A retrospective cohort study on clinical outcomes. Annals of Medicine and Surgery, 2016, 6, 36-41.	0.5	3
496	Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection—do N3 patients benefit from additional radiation?. British Journal of Radiology, 2016, 89, 20150758.	1.0	10
497	Advances in the Management of Gastric and Gastroesophageal Cancers. Current Oncology Reports, 2016, 18, 13.	1.8	7
498	Surgical management of advanced gastric cancer: An evolving issue. European Journal of Surgical Oncology, 2016, 42, 18-27.	0.5	76
499	Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy. BMC Cancer, 2016, 16, 29.	1.1	1
500	The 100 most influential manuscripts in gastric cancer: A bibliometric analysis. International Journal of Surgery, 2016, 28, 83-90.	1.1	55
501	Gastric and Duodenal Surgery. , 2016, , 299-331.		0
502	Report of two Cases with Metastasis in Lymph NodesAlong the Posterior Leaf of the Bursa Omentalis at the Area of the Pancreatic Body, an Area not Routinely Examined in Standard Gastrectomy Plus Bursectomy for Advanced Gastric Cancer. Journal of Gastrointestinal Cancer, 2016, 47, 436-441.	0.6	0
503	Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 1934-1940.	0.7	38
504	Illustrative Handbook of General Surgery. , 2016, , .		1
505	Is There Any Role of Adjuvant Chemotherapy for T3NOMO or T1N2MO Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?. Annals of Surgical Oncology, 2016, 23, 1234-1243.	0.7	18
506	Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer. Digestive Surgery, 2016, 33, 121-128.	0.6	43
508	Feasibility of Total Gastrectomy with D2 Lymphadenectomy for Gastric Cancer and Predictive Factors for Its Short- and Long-Term Outcomes. Journal of Gastrointestinal Surgery, 2016, 20, 521-530.	0.9	3
509	Retrospective assessment of patterns of recurrence relative to radiotherapy volumes for adjuvant conformal chemoradiotherapy in gastric cancer. Gastric Cancer, 2016, 19, 887-893.	2.7	4
510	ls signet-ring cell carcinoma a specific entity among gastric cancers?. Gastric Cancer, 2016, 19, 1027-1040.	2.7	60
511	Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?. Annals of Surgical Oncology, 2016, 23, 626-632.	0.7	15
512	Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center. European Journal of Surgical Oncology, 2016, 42, 94-102.	0.5	9
513	Targeting HER 2 and angiogenesis in gastric cancer. Expert Review of Anticancer Therapy, 2016, 16, 111-122.	1.1	15

#	Article	IF	CITATIONS
514	Predicting recurrence after curative resection for gastric cancer. European Journal of Surgical Oncology, 2016, 42, 123-131.	0.5	17
515	Postoperative sepsis in cancer patients undergoing major elective digestive surgery is associated with increased long-term mortality. Journal of Critical Care, 2016, 31, 48-53.	1.0	37
516	What can we learn from oncology surgical trials?. Nature Reviews Clinical Oncology, 2016, 13, 55-62.	12.5	29
517	S-I combined with cisplatin plus concurrent chemoradiotherapy versus cisplatin plus concurrent chemoradiotherapy for Chinese patients with advanced gastric cancer: a multi-centre randomized controlled trial. Clinical and Translational Oncology, 2016, 18, 672-676.	1.2	2
518	Impact of preoperative hand grip strength on morbidity following gastric cancer surgery. Gastric Cancer, 2016, 19, 1008-1015.	2.7	66
519	Ginsenoside Rg3 induces FUT4-mediated apoptosis in H. pylori CagA-treated gastric cancer cells by regulating SP1 and HSF1 expressions. Toxicology in Vitro, 2016, 31, 158-166.	1.1	47
520	Sentinel lymph node mapping for 385 gastric cancer patients. Journal of Surgical Research, 2016, 200, 73-81.	0.8	24
521	Comparison of the long-term results of patients who underwent laparoscopy versus open distal gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 430-436.	1.3	13
522	Factors Associated With Recurrence and Survival in NO Gastric Cancer. Annals of Surgery, 2017, 266, e10-e11.	2.1	3
523	Local resection of the stomach for gastric cancer. Surgery Today, 2017, 47, 651-659.	0.7	16
524	Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 375-380.	0.6	8
525	Is radical surgery necessary in all patients who do not meet the curative criteria for endoscopic submucosal dissection in early gastric cancer? A multi-center retrospective study in Japan. Journal of Gastroenterology, 2017, 52, 175-184.	2.3	111
526	Reply. Annals of Surgery, 2017, 266, e11.	2.1	0
527	Strategies to improve local control of resected pancreas adenocarcinoma. Surgical Oncology, 2017, 26, 63-70.	0.8	16
528	Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery. European Journal of Surgical Oncology, 2017, 43, 801-807.	0.5	22
529	Current Progress in the Adjuvant Treatment of Gastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 225-239.	0.6	11
530	Gastric cancer management: Kinases as a target therapy. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 613-622.	0.9	24
531	Short-Term Outcome in Patients Undergoing Gastrectomy with D2 Lymphadenectomy for Carcinoma Stomach. Indian Journal of Surgical Oncology, 2017, 8, 304-311.	0.3	3

#	Article	IF	CITATIONS
532	Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. British Journal of Surgery, 2017, 104, 877-884.	0.1	34
533	A High Lymph Node Yield is Associated with Prolonged Survival in Elderly Patients Undergoing Curative Gastrectomy for Cancer: A Dutch Population-Based Cohort Study. Annals of Surgical Oncology, 2017, 24, 2213-2223.	0.7	20
534	The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 213-224.	0.6	1
535	Differences in the multimodal treatment of gastric cancer: East versus west. Journal of Surgical Oncology, 2017, 115, 603-614.	0.8	72
536	Incidence and Prognostic Value of Metastases to "Posterior―and Para-aortic Lymph Nodes in Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 2273-2280.	0.7	15
537	Semiâ€endâ€toâ€end esophagojejunostomy after laparoscopyâ€assisted total gastrectomy better reduces stricture and leakage than the conventional endâ€toâ€side procedure: A retrospective study. Journal of Surgical Oncology, 2017, 116, 177-183.	0.8	10
538	Gastroduodenal and pancreatic surgeries: indications, surgical techniques, and imaging features. Abdominal Radiology, 2017, 42, 2054-2068.	1.0	2
541	Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. British Journal of Surgery, 2017, 104, 1226-1234.	0.1	9
542	Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. Clinical and Translational Oncology, 2017, 19, 1268-1275.	1.2	6
543	A Feasibility Study and Technical Tips for the Use of an Articulating Bipolar Vessel Sealer in da Vinci Robot-Assisted Gastrectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 1172-1179.	0.5	9
544	Addition of peritonectomy to gastrectomy can predict good prognosis of gastric adenocarcinoma patients with intraoperatively proven single P1/P2 carcinomatosis. Tumor Biology, 2017, 39, 101042831769756.	0.8	1
545	Gastric adenocarcinoma. Nature Reviews Disease Primers, 2017, 3, 17036.	18.1	409
546	A Nomogram for Predicting Overall Survival of Gastric Cancer Patients with Insufficient Lymph Nodes Examined. Journal of Gastrointestinal Surgery, 2017, 21, 947-956.	0.9	14
547	Technology Beats the Current Standard: Is Robotic Gastrectomy Becoming the Standard Treatment Option for Gastric Cancer?. Annals of Surgical Oncology, 2017, 24, 1755-1757.	0.7	1
548	Amylase concentration in drainage fluid as a predictive factor for severe postoperative pancreatic fistula in patients with gastric cancer. Surgery Today, 2017, 47, 1378-1383.	0.7	13
549	Beyond precision surgery: Molecularly motivated precision care for gastric cancer. European Journal of Surgical Oncology, 2017, 43, 856-864.	0.5	13
550	Lymph node ratio as a prognostic factor in gastric cancer patients following D1 resection. Comparison with the current TNM staging system. European Journal of Surgical Oncology, 2017, 43, 1350-1356.	0.5	20
551	Development and external validation of preoperative risk models for operative morbidities after total gastrectomy using a Japanese web-based nationwide registry. Gastric Cancer, 2017, 20, 987-997.	2.7	46

#	Article	IF	CITATIONS
552	Surgical Considerations in the Management of Gastric Adenocarcinoma. Surgical Clinics of North America, 2017, 97, 295-316.	0.5	8
553	East Versus West. Surgical Clinics of North America, 2017, 97, 453-466.	0.5	8
554	Can lymphovascular invasion be predicted by preoperative multiphasic dynamic CT in patients with advanced gastric cancer?. European Radiology, 2017, 27, 3383-3391.	2.3	35
555	Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. Journal of the American College of Surgeons, 2017, 224, 546-555.	0.2	74
556	Why should we perform a D2 lymphadenectomy in gastric cancer?. Future Oncology, 2017, 13, 2009-2012.	1.1	5
557	The pattern of lymph node metastases in microsatellite unstable gastric cancer. European Journal of Surgical Oncology, 2017, 43, 2341-2348.	0.5	19
559	Is it necessary to dissect the posterior lymph nodes along the splenic vessels during total gastrectomy with D2 lymphadenectomy for advanced gastric cancer?. European Journal of Surgical Oncology, 2017, 43, 2357-2365.	0.5	10
560	Surgical outcome evaluation of perforated gastric cancer: from the aspects of both acute care surgery and surgical oncology. Scandinavian Journal of Gastroenterology, 2017, 52, 1371-1376.	0.6	10
561	Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1563-1570.	0.9	7
562	Chemotherapy for advanced gastric cancer. The Cochrane Library, 2017, 2017, CD004064.	1.5	662
563	Open Versus Hand-assisted Laparoscopic Total Gastric Resection With D2 Lymph Node Dissection for Adenocarcinoma: A Case-Control Study. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2017, 27, 42-50.	0.4	9
564	Comparison of quality of life between Billroth-D† and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: A randomized controlled trial. Scientific Reports, 2017, 7, 11245.	1.6	34
565	Treatment of lymph node metastases from gastric cancer with a combination of Irreversible Electroporation and Electrochemotherapy: a case report. Clinical Case Reports (discontinued), 2017, 5, 1389-1394.	0.2	10
566	Precision medicine in gastric cancer: where are we now?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 193-204.	0.4	O
567	The retrieval of at least 25 lymph nodes should be essential for advanced gastric cancer patients with lymph node metastasis: A retrospective analysis of single-institution database study design: Cohort study. International Journal of Surgery, 2017, 48, 291-299.	1.1	14
568	Developments in optical imaging for gastrointestinal surgery. Future Oncology, 2017, 13, 2363-2382.	1.1	6
569	Survival Rates for Patients with Resected Gastric Adenocarcinoma Finally have Increased in the United States. Annals of Surgical Oncology, 2017, 24, 3361-3367.	0.7	11
570	A strategy for actualization of active targeting nanomedicine practically functioning in a living body. Biomaterials, 2017, 141, 136-148.	5.7	9

#	Article	IF	CITATIONS
571	Adjuvant radiochemotherapy in locally advanced gastric cancer. Strahlentherapie Und Onkologie, 2017, 193, 1005-1013.	1.0	2
573	Laparoscopic gastrectomy in obese gastric cancer patients: a comparative study with non-obese patients and evaluation of difference in laparoscopic methods. BMC Gastroenterology, 2017, 17, 78.	0.8	20
574	Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis. World Journal of Surgical Oncology, 2017, 15, 113.	0.8	34
575	Fibroblast Activation Protein-α-Positive Fibroblasts Promote Gastric Cancer Progression and Resistance to Immune Checkpoint Blockade. Oncology Research, 2017, 25, 629-640.	0.6	69
576	Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2–4 gastric cancer. Gastric Cancer, 2017, 20, 736-743.	2.7	19
577	Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent. American Journal of Surgery, 2017, 213, 120-126.	0.9	50
578	Increasing the Number of Examined Lymph Nodes is a Prerequisite for Improvement in the Accurate Evaluation of Overall Survival of Node-Negative Gastric Cancer Patients. Annals of Surgical Oncology, 2017, 24, 745-753.	0.7	59
579	Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma. Annals of Surgical Oncology, 2017, 24, 425-433.	0.7	24
580	Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy. Journal of Gastrointestinal Cancer, 2017, 48, 31-37.	0.6	5
581	Gastric carcinoma in canines and humans, a review. Veterinary and Comparative Oncology, 2017, 15, 692-705.	0.8	27
582	Oncological outcomes of function-preserving gastrectomy for early gastric cancer: a multicenter propensity score matched cohort analysis comparing pylorus-preserving gastrectomy versus conventional distal gastrectomy. Gastric Cancer, 2017, 20, 709-717.	2.7	30
583	Evaluation of prognostic value and stage migration effect using positive lymph node ratio in gastric cancer. European Journal of Surgical Oncology, 2017, 43, 203-209.	0.5	25
584	Outcomes of octogenarians undergoing gastrectomy performed for malignancy. Journal of Surgical Research, 2017, 207, 1-6.	0.8	10
585	18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma. European Journal of Surgical Oncology, 2017, 43, 196-202.	0.5	19
586	Robotic gastrectomy versus open gastrectomy in the treatment of gastric cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 105-114.	1.2	23
587	Modified vs. standard D2 lymphadenectomy in distal subtotal gastrectomy for locally advanced gastric cancer patients under 70 years of age. Oncology Letters, 2017, 15, 375-385.	0.8	3
588	Blood type AB predicts promising prognosis in gastric cancer patients with positive preoperative serum CEA. Medicine (United States), 2017, 96, e8496.	0.4	4
590	Survival Analysis with Extended Lymphadenectomy for Gastric Cancer: Removing Stage Migration from the Equation. American Surgeon, 2017, 83, 1074-1079.	0.4	10

#	Article	IF	Citations
591	External Validation of a Gastric Cancer Nomogram Derived from a Large-volume Center Using Dataset from a Medium-volume Center. Journal of Gastric Cancer, 2017, 17, 204.	0.9	3
592	Gastric Adenocarcinoma: A Multimodal Approach. Frontiers in Surgery, 2017, 4, 42.	0.6	12
593	Staging and Surgical Approaches in Gastric Cancer: A Clinical Practice Guideline. Current Oncology, 2017, 24, 324-331.	0.9	39
594	Laparoscopic distal gastrectomy with D2 lymphadenectomy followed by intracorporeal gastroduodenostomy for advanced gastric cancer: technical guide and tips. Translational Gastroenterology and Hepatology, 2017, 2, 84-84.	1.5	6
595	Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis. Journal of Cancer, 2017, 8, 2231-2237.	1.2	11
596	Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. Journal of Gastric Cancer, 2017, 17, 21.	0.9	10
597	Status and Prospects of Robotic Gastrectomy for Gastric Cancer: Our Experience and a Review of the Literature. Gastroenterology Research and Practice, 2017, 2017, 1-11.	0.7	7
598	Prognostic Discrepancy of the 6th and 7th UICC N Classification for Lymph Node Staging in Gastric Cancer Patients after Curative Resection. Case Reports in Oncology, 2017, 10, 57-65.	0.3	4
599	Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aNOMO Gastric Cancer Patients after D2 Gastrectomy. Gastroenterology Research and Practice, 2017, 2017, 1-9.	0.7	5
600	Prognostic significance of the total number of harvested lymph nodes for lymph node-negative gastric cancer patients. BMC Cancer, 2017, 17, 558.	1.1	18
601	Evolution in the surgical management of gastric cancer: is extended lymph node dissection back in vogue in the USA?. World Journal of Surgical Oncology, 2017, 15, 135.	0.8	9
602	FBXO50 Enhances the Malignant Behavior of Gastric Cancer Cells. Annals of Surgical Oncology, 2017, 24, 3771-3779.	0.7	19
604	Lymphadenectomy in elderly/high risk patients: should it be different?. Translational Gastroenterology and Hepatology, 2017, 2, 5-5.	1.5	9
605	Greater Lymph Node Retrieval Improves Survival in Node-Negative Resected Gastric Cancer in the United States. Journal of Gastric Cancer, 2017, 17, 306.	0.9	19
606	Lymphadenectomy: state of the art. Translational Gastroenterology and Hepatology, 2017, 2, 3-3.	1.5	5
607	Gastric Cancer in Asia: Unique Features and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 279-291.	1.8	27
608	Recent trends of gastric cancer treatment in Turkey. Translational Gastroenterology and Hepatology, 2017, 2, 31-31.	1.5	8
609	Gastric cancer treatment: similarity and difference between China and Korea. Translational Gastroenterology and Hepatology, 2017, 2, 36-36.	1.5	20

#	Article	IF	CITATIONS
610	Prognostic impact of nodal status and therapeutic implications. Translational Gastroenterology and Hepatology, 2017, 2, 15-15.	1.5	8
611	Effect of Helicobacter pylori infection on outcomes in resected gastric and gastroesophageal junction cancer. Journal of Gastrointestinal Oncology, 2017, 8, 583-588.	0.6	9
612	Notes on laparoscopic gastrointestinal surgeryâ€"current status from clinical studies of minimally invasive surgery for gastric cancer. Journal of Visualized Surgery, 2017, 2, 14-14.	0.2	2
613	Laparoscopic sentinel node navigation surgery for early gastric cancer. Translational Gastroenterology and Hepatology, 2017, 2, 42-42.	1.5	13
614	Survival impact of the number of lymph node retrieved on patients with node-negative gastric cancer: more is better?. Translational Gastroenterology and Hepatology, 2017, 2, 103-103.	1.5	3
615	Risk factors for metastasis to No.14v lymph node and prognostic value of 14v status for gastric cancer patients after surgery. Japanese Journal of Clinical Oncology, 2018, 48, 335-342.	0.6	12
616	Diagnostic evaluation of sentinel lymph node biopsy using indocyanine green and infrared or fluorescent imaging in gastric cancer: a systematic review and meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 2620-2631.	1.3	46
617	Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. Journal of Gastrointestinal Surgery, 2018, 22, 1325-1333.	0.9	14
618	Severity of complications and long-term survival after laparoscopic total gastrectomy with D2 lymph node dissection for advanced gastric cancer: A propensity score-matched, case–control study. International Journal of Surgery, 2018, 54, 62-69.	1.1	33
619	Beyond T, N and M: The impact of tumor deposits on the staging and treatment of colorectal and gastric carcinoma. Surgical Oncology, 2018, 27, 129-137.	0.8	19
620	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 616-628.	5.1	397
621	Comparison of East and West Survival Nomograms in Turkish Gastric Cancer Patients Who Underwent Radical Surgery. Scandinavian Journal of Surgery, 2018, 107, 308-314.	1.3	3
622	Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial. British Journal of Surgery, 2018, 105, 728-735.	0.1	36
623	Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study. Annals of Surgical Oncology, 2018, 25, 1176-1183.	0.7	27
625	Gap-enhanced Raman tags for high-contrast sentinel lymph node imaging. Biomaterials, 2018, 163, 105-115.	5.7	56
626	The optimal lymph node dissection in patients with adenocarcinoma of the esophagogastric junction. Surgical Oncology, 2018, 27, 36-43.	0.8	11
627	The impact of advanced age on short-term outcomes following gastric cancer resection: an ACS-NSQIP analysis. Gastric Cancer, 2018, 21, 710-719.	2.7	28
628	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Critical Reviews in Oncology/Hematology, 2018, 122, 179-193.	2.0	57

#	Article	IF	CITATIONS
629	Gastric Cancer (Siewert Type III). Practical Guides in Radiation Oncology, 2018, , 53-91.	0.0	0
630	Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. BMC Cancer, 2018, 18, 73.	1.1	47
631	Lymphovascular invasion as a predictor for lymph node metastasis and a prognostic factor in gastric cancer patients under 70 years of age: A retrospective analysis. International Journal of Surgery, 2018, 53, 214-220.	1.1	28
632	Surgical outcomes after gastrectomy in very elderly patients with gastric cancer. Surgery Today, 2018, 48, 773-782.	0.7	17
633	Determining the Adequate Examined Lymph Node Count in Resected Ampullary Adenocarcinoma—A National Cohort Study. Journal of Gastrointestinal Surgery, 2018, 22, 792-801.	0.9	3
634	Distal versus total gastrectomy for middle and lower-third gastric cancer: A systematic review and meta-analysis. International Journal of Surgery, 2018, 53, 163-170.	1.1	33
635	Gastrectomy with limited surgery for elderly patients with gastric cancer. Asian Journal of Surgery, 2018, 41, 65-72.	0.2	10
636	Laparoscopy-assisted versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer. Annals of Surgery, 2018, 267, 638-645.	2.1	148
637	Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer, 2018, 21, 338-344.	2.7	31
638	Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Annals of Surgery, 2018, 267, 105-113.	2.1	103
639	An Experience of Radical Gastrectomy in Indian Patients with Gastric Carcinoma. Indian Journal of Surgery, 2018, 80, 452-456.	0.2	0
640	Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis. Gastric Cancer, 2018, 21, 391-400.	2.7	40
641	Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?. Gastric Cancer, 2018, 21, 446-452.	2.7	33
642	Anatomical location of metastatic lymph nodes: an indispensable prognostic factor for gastric cancer patients who underwent curative resection. Scandinavian Journal of Gastroenterology, 2018, 53, 185-192.	0.6	15
643	Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treatment Reviews, 2018, 63, 104-115.	3.4	98
644	Radical gastric cancer surgery results in widespread upregulation of proâ€tumourigenic intraperitoneal cytokines. ANZ Journal of Surgery, 2018, 88, E370-E376.	0.3	5
645	Comparison of Surgical Outcomes Between Robotic and Laparoscopic Distal Gastrectomy for cT1 Gastric Cancer. World Journal of Surgery, 2018, 42, 1803-1810.	0.8	36
646	Universalization of the operative strategy by systematic mesogastric excision for stomach cancer with that for total mesorectal excision and complete mesocolic excision colorectal counterparts.  Annals of Gastroenterological Surgery, 2018, 2, 28-36.	1.2	31

#	Article	IF	CITATIONS
647	Gastrectomy with Extended Lymphadenectomy: a North American Perspective. Journal of Gastrointestinal Surgery, 2018, 22, 414-420.	0.9	5
648	Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma?. Journal of Surgical Oncology, 2018, 117, 659-670.	0.8	10
650	Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. Annals of Surgery, 2018, 268, 1008-1013.	2.1	27
651	Prognostic significance of suprapancreatic lymph nodes and its implication on D2 dissection. Medicine (United States), 2018, 97, e11092.	0.4	3
652	Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study. World Journal of Clinical Cases, 2018, 6, 373-383.	0.3	6
653	Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country. Journal of Gastrointestinal Oncology, 2018, 9, 64-72.	0.6	7
654	Gastric cancer lymph node resectionâ€"the more the merrier?. Translational Gastroenterology and Hepatology, 2018, 3, 1-1.	1.5	14
655	How many lymph nodes are enough?—defining the extent of lymph node dissection in stage l–III gastric cancer using the National Cancer Database. Journal of Gastrointestinal Oncology, 2018, 9, 1168-1175.	0.6	8
657	A propensity score-matched comparison of laparoscopic distal versus total gastrectomy for middle-third advanced gastric cancer. International Journal of Surgery, 2018, 60, 194-203.	1.1	7
658	Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database. BMC Cancer, 2018, 18, 1064.	1.1	8
659	Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. Annals of Gastroenterology, 2018, 32, 99-106.	0.4	6
660	Surgical treatment of gastric cancer: a 10-year experience in a high-volume university hospital. Clinics, 2018, 73, e543s.	0.6	35
661	Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. Journal of Gastrointestinal Oncology, 2018, 9, 560-572.	0.6	9
662	Preoperative Nodal <sup>18</sup> F-FDG Avidity Rather than Primary Tumor Avidity Determines the Prognosis of Patients with Advanced Gastric Cancer. Journal of Gastric Cancer, 2018, 18, 218.	0.9	6
663	A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer. Anticancer Research, 2018, 38, 6015-6021.	0.5	4
664	Characterization of an orthotopic gastric cancer mouse model with lymph node and organ metastases using bioluminescence imaging. Oncology Letters, 2018, 16, 5179-5185.	0.8	8
665	Cutting-edge evidence of adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1109-1122.	1.4	3
667	Does high body mass index negatively affect the surgical outcome and long-term survival of gastric cancer patients who underwent gastrectomy: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2018, 44, 1971-1981.	0.5	32

#	Article	IF	CITATIONS
668	Reporting of outcomes in gastric cancer surgery trials: a systematic review. BMJ Open, 2018, 8, e021796.	0.8	21
669	Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer. Annals of Gastroenterological Surgery, 2018, 2, 400-405.	1.2	28
670	Progress of preoperative and postoperative radiotherapy in gastric cancer. World Journal of Surgical Oncology, 2018, 16, 187.	0.8	29
671	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer, 2018, 18.877.	1.1	115
673	Extensive intraperitoneal lavage to eliminate intraperitoneal tumor cells in gastrectomy with D2 lymphadenectomy for gastric cancer. Tumori, 2018, 104, 361-368.	0.6	7
674	The effect of preoperative treatments on lymph node counts after total gastrectomy in esophagogastric adenocarcinoma. Journal of Surgical Oncology, 2018, 118, 657-663.	0.8	3
675	Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery. Journal of Cancer, 2018, 9, 81-91.	1.2	20
676	Laparoscopic versus open gastrectomy for advanced gastric cancer: A meta-analysis based on high-quality retrospective studies and clinical randomized trials. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 577-590.	0.7	32
677	Statistically but not clinically significant? Biomarkers in gastric cancer. Clinical Nutrition, 2018, 37, 2292-2293.	2.3	4
678	Intraoperative pancreatic injury gives rise to severe postoperative pancreatic fistula: Results of a review of unedited videos of the laparoscopic surgical procedures. International Surgery, 2018, , .	0.0	1
680	A Randomized Controlled Trial of Running Versus Interrupted Subcuticular Sutures for Skin Closure in Open Gastric Surgery. International Surgery, 2018, 103, 305-314.	0.0	0
683	Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials. Clinical and Experimental Metastasis, 2018, 35, 431-442.	1.7	16
684	Adjuvant therapy in resectable gastric cancerâ€"the CRITICS trial. Lancet Oncology, The, 2018, 19, e330.	5.1	7
685	Radiation Therapy in Gastric Cancer. , 2018, , 1-13.		0
686	Multimodal treatment in locally advanced gastric cancer. Updates in Surgery, 2018, 70, 173-179.	0.9	44
687	Compliance to D2 lymphadenectomy in laparoscopic gastrectomy. Updates in Surgery, 2018, 70, 197-205.	0.9	12
688	Favoring D2-Lymphadenectomy in Gastric Cancer. Frontiers in Surgery, 2018, 5, 42.	0.6	14
689	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. Radiotherapy and Oncology, 2018, 129, 306-312.	0.3	12

#	Article	IF	CITATIONS
690	A comparison of the operative outcomes of D1 and D2 gastrectomy performed at a single Western center with multiple surgeons: a retrospective analysis with propensity score matching. World Journal of Surgical Oncology, 2018, 16, 136.	0.8	15
691	Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report. Oncology Letters, 2018, 16, 2085-2090.	0.8	8
692	Robotic versus laparoscopic gastrectomy with D2 lymph node dissection for advanced gastric cancer: a propensity score-matched analysis. Cancer Management and Research, 2018, Volume 10, 705-714.	0.9	41
693	Characteristics and survival outcomes related to the infra-pyloric lymph node status of gastric cancer patients. World Journal of Surgical Oncology, 2018, 16, 116.	0.8	10
694	Estado actual de la gastrectomÃa por cáncer. «Less is often more». CirugÃa Española, 2018, 96, 603-605.	0.1	1
695	Surgery with curative intent for stage IV gastric cancer: Is it a reality of illusion?. Annals of Gastroenterological Surgery, 2018, 2, 339-347.	1.2	16
696	Bursectomy for advanced gastric cancer: an update meta-analysis. World Journal of Surgical Oncology, 2018, 16, 66.	0.8	8
697	Pancreatic Complications After Conventional Laparoscopic Radical Gastrectomy Versus Robotic Radical Gastrectomy: Systematic Review and Meta-Analysis. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2018, 28, 1207-1215.	0.5	18
698	Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?. World Journal of Gastroenterology, 2018, 24, 274-289.	1.4	88
699	Combination of CRP and NLR: a better predictor of postoperative survival in patients with gastric cancer. Cancer Management and Research, 2018, Volume 10, 315-321.	0.9	41
700	Current challenges in gastric cancer surgery: European perspective. Surgical Oncology, 2018, 27, 650-656.	0.8	25
701	Reevaluation of laparoscopic versus open distal gastrectomy for early gastric cancer in Asia: A meta-analysis of randomized controlled trials. International Journal of Surgery, 2018, 56, 31-43.	1.1	21
702	Do all the European surgeons perform the same D2? The need of D2 audit in Europe. Updates in Surgery, 2018, 70, 189-195.	0.9	7
703	Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digestive and Liver Disease, 2018, 50, 768-779.	0.4	73
704	Feasibility of Laparoscopic Distal Gastrectomy for Stage I Gastric Cancer in Patients Outside of Clinical Trials. Journal of Gastrointestinal Surgery, 2018, 22, 1665-1671.	0.9	3
705	Prognostic factors in patients with gastric adenocarcinoma using competing-risk analysis: a study of cases in the SEER database. Scandinavian Journal of Gastroenterology, 2019, 54, 1015-1021.	0.6	6
706	Characterization of the prognostic values of the <i>NDRG </i> family in gastric cancer. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985850.	1.4	44
707	Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. World Journal of Gastrointestinal Oncology, 2019, 11, 509-517.	0.8	21

#	Article	IF	CITATIONS
709	Twenty-year survival of gastric cancer with peritoneal metastases using long-term normothermic intraperitoneal 5-fluorouracil and systemic mitomycin C: A case report. International Journal of Surgery Case Reports, 2019, 61, 302-304.	0.2	1
710	Postoperative complications and nutritional status between uncut Roux-en-Y anastomosis and Billroth II anastomosis after D2 distal gastrectomy: a study protocol for a multicenter randomized controlled trial. Trials, 2019, 20, 428.	0.7	10
711	Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy. Radiation Oncology, 2019, 14, 128.	1.2	20
712	The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. Journal of Cancer, 2019, 10, 3094-3101.	1.2	9
713	Total gastrectomy in patients with gastric adenocarcinoma: Is there an advantage to the minimally invasive approach?. Surgery, 2019, 166, 623-631.	1.0	11
714	Staging systems for gastric cancer: more complex than TNM. Translational Gastroenterology and Hepatology, 2019, 4, 44-44.	1.5	1
715	Characterization of the prognostic values of CXCR family in gastric cancer. Cytokine, 2019, 123, 154785.	1.4	21
716	Performance of a machine learning-based decision model to help clinicians decide the extent of lymphadenectomy (D1 vs. D2) in gastric cancer before surgical resection. Abdominal Radiology, 2019, 44, 3019-3029.	1.0	18
717	Systematic review and meta-analysis of splenectomy in gastrectomy for gastric carcinoma. International Journal of Surgery, 2019, 68, 104-113.	1.1	8
718	Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction. British Journal of Surgery, 2019, 106, 1204-1215.	0.1	6
719	Surgery After Neoadjuvant Chemotherapy., 2019,, 245-251.		0
720	Adjuvant Treatment for Gastric Cancer. , 2019, , 353-357.		0
721	Radiation Therapy for Gastric Cancer. , 2019, , 359-366.		0
722	Robotic-assisted gastrectomy for gastric cancer: a European perspective. Gastric Cancer, 2019, 22, 909-919.	2.7	55
723	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (â‰ <b>4</b> 5 Years) With Gastric Cancer. Anticancer Research, 2019, 39, 5811-5820.	0.5	6
724	Laparoscopic surgery facilitates administration of adjuvant chemotherapy in locally advanced colon cancer: propensity score analyses. Cancer Management and Research, 2019, Volume 11, 7141-7157.	0.9	10
725	Survival analysis according to lymph nodes dissection and adjuvant therapy types in gastric cancer: A retrospective multicenter cohort study. Journal of Oncological Science, 2019, 5, 80-84.	0.1	0
726	Preoperative N stage evaluation in advanced gastric cancer patients using multidetector CT: can the sum of the diameters of metastatic LNs be used for N stage evaluation?. Clinical Radiology, 2019, 74, 782-789.	0.5	7

#	Article	IF	Citations
727	Adjuvant Chemotherapy of Gastric Cancer., 2019,,.		0
728	Usefulness of histologic differences and perivascular infiltration for preoperative T staging of advanced gastric cancer using computed tomography. Japanese Journal of Radiology, 2019, 37, 817-825.	1.0	3
729	In-Hospital Mortality Risk Model of Gastric Cancer Surgery: Analysis of a Nationwide Institutional-Level Database With 94,277 Chinese Patients. Frontiers in Oncology, 2019, 9, 846.	1.3	1
730	Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors. Scientific Reports, 2019, 9, 15806.	1.6	9
731	Is D2 Lymphadenectomy Essential for Cytology-positive Gastric Cancer? A Retrospective Analysis. Anticancer Research, 2019, 39, 6209-6216.	0.5	3
732	Positive nodeâ€ratio in curativeâ€intent treatment for gastric cancer is a strong independent prognostic factor for 5â€year overall survival. Journal of Surgical Oncology, 2020, 121, 777-783.	0.8	7
733	Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia. Expert Review of Anticancer Therapy, 2019, 19, 939-945.	1.1	6
734	3D Honeycomb Architecture Enables a Highâ€Rate and Longâ€Life Iron (III) Fluoride–Lithium Battery. Advanced Materials, 2019, 31, e1905146.	11.1	84
736	Impact of postoperative major complications on long-term survival after radical resection of gastric cancer. BMC Cancer, 2019, 19, 833.	1.1	39
737	ASO Author Reflections: Effect of Noncompliance in Lymph Node Dissection on the Long-Term Survival of Gastric Cancer Patients After Radical Gastrectomy. Annals of Surgical Oncology, 2019, 26, 719-720.	0.7	0
738	Retrieved lymph nodes from different anatomic groups in gastric cancer: a proposed optimal number, comparison with other nodal classification strategies and its impact on prognosis. Cancer Communications, 2019, 39, 1-12.	3.7	14
739	Systematic assessment of complications after robotic-assisted total versus distal gastrectomy for advanced gastric cancer: A retrospective propensity score-matched study using Clavien–Dindo classification. International Journal of Surgery, 2019, 71, 140-148.	1.1	16
740	Attachment orientations, filial piety and future parent support provision among Mainland Chinese college students. Current Psychology, 2023, 42, 15958-15966.	1.7	7
741	A sixâ€micro RNA signature to predict outcomes of patients with gastric cancer. FEBS Open Bio, 2019, 9, 538-547.	1.0	6
742	Intraoperative blood loss does not independently affect the survival outcome of gastric cancer patients who underwent curative resection. Clinical and Translational Oncology, 2019, 21, 1197-1206.	1.2	15
743	Predictors of survival outcome following radical gastrectomy for gastric cancer. ANZ Journal of Surgery, 2019, 89, 84-89.	0.3	9
745	Prognostic Value of the Nutritional Risk Screening 2002 Scale in Metastatic Gastric Cancer: A Large-Scale Cohort Study. Journal of Cancer, 2019, 10, 112-119.	1.2	23
746	Long-term oncological outcomes in laparoscopic versus open gastrectomy for advanced gastric cancer: A meta-analysis of high-quality nonrandomized studies. American Journal of Surgery, 2019, 218, 631-638.	0.9	13

#	Article	lF	Citations
747	Gastric cancer surgery: clinical outcomes and prognosis are influenced by perioperative blood transfusions. Updates in Surgery, 2019, 71, 439-443.	0.9	6
<b>7</b> 49	Open Surgery for Gastric Cancer: Distal Subtotal Gastrectomy with D2 Lymph Node Dissection. , 2019, , 99-110.		0
750	Neoadjuvant Treatment for Gastric Cancer. , 2019, , 343-352.		O
751	Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database. Annals of Surgical Oncology, 2019, 26, 2722-2729.	0.7	23
752	Multimodality management of locally advanced gastric cancerâ€"the timing and extent of surgery. Translational Gastroenterology and Hepatology, 2019, 4, 42-42.	1.5	14
<b>7</b> 53	Updates on Management of Gastric Cancer. Current Oncology Reports, 2019, 21, 67.	1.8	292
754	Perioperative complications and outcome after surgery for treatment of gastric carcinoma in dogs: A Veterinary Society of Surgical Oncology retrospective study of 40 cases (2004–2018). Veterinary Surgery, 2019, 48, 923-932.	0.5	13
755	Laparoscopic Surgery for Gastric Cancer, Total Gastrectomy with D2 Lymph Node Dissection. , 2019, , 153-158.		0
756	Invited Commentary. Journal of the American College of Surgeons, 2019, 228, 891-892.	0.2	0
757	Gastric Cancer – From Aetiology to Management: Differences Between the East and the West. Clinical Oncology, 2019, 31, 570-577.	0.6	22
758	Combined Modality Treatment for Locally Advanced Gastric Cancer: Current Evidences and New Perspectives. Current Clinical Pathology, 2019, , 133-145.	0.0	0
759	Surgical Strategies in Gastric Cancer. Current Clinical Pathology, 2019, , 147-152.	0.0	0
760	Gastric Adenocarcinoma. , 2019, , 712-718.		1
761	Lymph node count impacts survival following postâ€chemotherapy retroperitoneal lymphadenectomy for nonâ€seminomatous testicular cancer: a populationâ€based analysis. BJU International, 2019, 124, 792-800.	1.3	12
762	Radiomics Signature on Computed Tomography Imaging: Association With Lymph Node Metastasis in Patients With Gastric Cancer. Frontiers in Oncology, 2019, 9, 340.	1.3	57
763	Is curative gastrectomy justified for gastric cancer with cytology positive as the only stage IV factor?. Langenbeck's Archives of Surgery, 2019, 404, 599-604.	0.8	5
764	In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection—D1 Versus D2 Versus D3?. Annals of Surgical Oncology, 2019, 26, 2912-2932.	0.7	20
765	Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. Journal of Gastrointestinal Oncology, 2019, 10, 314-323.	0.6	3

#	Article	IF	CITATIONS
766	Gastric Cancer In The Precision Medicine Era. Current Clinical Pathology, 2019, , .	0.0	2
767	Landmark Trials in Oncology. , 2019, , .		0
768	Development and external validation of a nomogram for predicting the conditional probability of survival after D2 lymphadenectomy for gastric cancer: A multicentre study. European Journal of Surgical Oncology, 2019, 45, 1934-1942.	0.5	11
769	Laparoscopic modified lymphadenectomy in gastric cancer surgery using systematic mesogastric excision: a novel technique based on a concept. Langenbeck's Archives of Surgery, 2019, 404, 369-374.	0.8	13
770	Staging of gastric cancer with the Clinical Stage Prediction score. World Journal of Surgical Oncology, 2019, 17, 47.	0.8	7
771	Prognostic Factors and Recurrence Patterns in T4 Gastric Cancer Patients after Curative Resection. Journal of Cancer, 2019, 10, 1181-1188.	1.2	21
772	Pumilaside A from Litchi semen induces apoptosis in human gastric cancer BGC823 cells via activation of death receptor- and mitochondria-mediated apoptotic pathways. Tropical Journal of Pharmaceutical Research, 2019, 17, 2405.	0.2	2
773	Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?. Clinical and Translational Oncology, 2019, 21, 1699-1706.	1.2	22
774	Additional gastrectomy in early-stage gastric cancer after non-curative endoscopic resection: a meta-analysis. Gastroenterology Report, 2019, 7, 91-97.	0.6	14
775	Recent trends from the results of clinical trials on gastric cancer surgery. Cancer Communications, 2019, 39, 1-7.	3.7	14
776	Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. Journal of Gastric Cancer, 2019, 19, 1.	0.9	328
777	Novel immune–risk score of gastric cancer: A molecular prediction model combining the value of immune–risk status and chemosensitivity. Cancer Medicine, 2019, 8, 2675-2685.	1.3	21
778	Management of Early Stage Gastric and Gastroesophageal Junction Malignancies. Surgical Clinics of North America, 2019, 99, 439-456.	0.5	6
779	Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. Journal of Cancer, 2019, 10, 458-466.	1.2	8
780	Techniques and Current Role of Sentinel Lymph Node (SLN) Concept in Gastric Cancer Surgery. Frontiers in Surgery, 2018, 5, 77.	0.6	11
781	Does Noncompliance in Lymph Node Dissection Affect Oncological Efficacy in Gastric Cancer Patients Undergoing Radical Gastrectomy?. Annals of Surgical Oncology, 2019, 26, 1759-1771.	0.7	18
782	TOTAL OMENTECTOMY IN GASTRIC CANCER SURGERY: IS IT ALWAYS NECESSARY?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2019, 32, e1425.	0.5	18
783	Reduced acute and late toxicities with intensity-modulated radiation therapy compared to three-dimensional conformal radiation therapy in post-operative gastric cancer. Journal of Radiation Oncology, 2019, 8, 73-80.	0.7	1

#	Article	IF	CITATIONS
784	Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. Yonsei Medical Journal, 2019, 60, 235.	0.9	11
785	Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation. Annals of Surgical Oncology, 2019, 26, 1292-1300.	0.7	12
786	Gastric cancer surgery: the importance of technique and not only the extent of lymph node dissection. Lancet Oncology, The, 2019, 20, 329-331.	5.1	7
787	Outcomes of Extended Lymphadenectomy for Gastroesophageal Carcinoma: A Large Western Series. Journal of the American College of Surgeons, 2019, 228, 879-891.	0.2	6
788	Optimal Timing for Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity Score Matching Study. Journal of Cancer, 2019, 10, 332-340.	1.2	13
789	Effect of Surgical Approach on Node Harvest in Robotic Gastrectomy. American Surgeon, 2019, 85, 794-799.	0.4	2
790	Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China. Frontiers in Oncology, 2019, 9, 1155.	1.3	13
791	Adjuvant Chemoradiotherapy for Gastric Cancer: Efficacy and Cost-Effectiveness Analysis. Frontiers in Oncology, 2019, 9, 1357.	1.3	3
792	Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Frontiers in Oncology, 2019, 9, 1308.	1.3	82
793	Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients. Cancers, 2019, 11, 1890.	1.7	11
794	Evaluation of D2-plus radical resection for gastric cancer with pyloric invasion. BMC Surgery, 2019, 19, 172.	0.6	3
795	Effect of laparoscopic vs. open distal gastrectomy on 3-year disease free survival in patients with locally advanced gastric cancer: commentary on the class-01 randomized clinical trial. Translational Gastroenterology and Hepatology, 2019, 4, 78-78.	1.5	7
796	Prognostic Impact of Extended Lymph Node Dissection versus Limited Lymph Node Dissection on pNO Proximal Advanced Gastric Cancer: a Propensity Score Matching Analysis. Journal of Gastric Cancer, 2019, 19, 212.	0.9	5
798	Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). Annals of Surgery, 2019, 270, 983-991.	2.1	322
799	Clinical significance of neutrophil-to-lymphocyte ratio as a predictor of lymph node metastasis in gastric cancer. BMC Cancer, 2019, 19, 1187.	1.1	19
800	Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer—an east and west multicenter study. BMC Gastroenterology, 2019, 19, 205.	0.8	6
801	The crossover technique for intracorporeal esophagojejunostomy following laparoscopic total gastrectomy: a simple and safe technique using a linear stapler and two barbed sutures. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 1386-1393.	1.3	17
802	Minimally Invasive Gastric Cancer Surgery. Surgical Oncology Clinics of North America, 2019, 28, 201-213.	0.6	19

#	Article	IF	CITATIONS
803	D2 lymphadenectomy for gastric cancer as an independent prognostic factor of 10-year overall survival. European Journal of Surgical Oncology, 2019, 45, 446-453.	0.5	9
804	Prognostic significance of tumour infiltration growth pattern in patients with advanced gastric cancer. Journal of Clinical Pathology, 2019, 72, 165-171.	1.0	6
805	Surgical Treatment: Evidence in Gastric Cancer Surgery Based on Japanese ClinicalÂTrials., 2019, , 161-172.		2
807	Fluorescent Lymphography–Guided Lymphadenectomy During Robotic Radical Gastrectomy for Gastric Cancer. JAMA Surgery, 2019, 154, 150.	2.2	115
808	The prognostic significance of macroscopic serosal change in subserosal invasion (stage T3) gastric cancer. Annals of the Royal College of Surgeons of England, 2019, 101, 249-255.	0.3	1
809	A Simplified Two-Step Technique for Extended Lymphadenectomy During Resection of Gastroesophageal Malignancy: Early Results Compared to En Bloc Dissection. Journal of Gastrointestinal Surgery, 2019, 23, 393-401.	0.9	1
810	Is the AJCC TNM staging system still appropriate for gastric cancer patients survival after 5 years?. European Journal of Surgical Oncology, 2019, 45, 1115-1120.	0.5	5
811	Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 6.	3.5	153
812	Clockwise, Modularized Lymphadenectomy in Laparoscopic Gastric Cancer Surgery: a New Laparoscopic Surgery Model. Journal of Gastrointestinal Surgery, 2019, 23, 895-903.	0.9	5
813	Gastric Cancer Etiology and Management in Asia and the West. Annual Review of Medicine, 2019, 70, 353-367.	5.0	114
814	Number of retrieved lymph nodes is an independent prognostic factor after total gastrectomy for patients with stage III gastric cancer: propensity score matching analysis of a multi-institution dataset. Gastric Cancer, 2019, 22, 853-863.	2.7	32
815	Surgical outcomes of gastrectomy with D1 lymph node dissection performed for patients with unfavorable clinical conditions. European Journal of Surgical Oncology, 2019, 45, 460-465.	0.5	22
816	Should All Stage N3b Patients with Advanced Gastric Cancer Be Considered Equivalent? A 30-Year Single Center Study. Journal of Gastrointestinal Surgery, 2019, 23, 1742-1747.	0.9	5
817	Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer. Pathology and Oncology Research, 2019, 25, 369-376.	0.9	33
818	Gastric cancer: factors affecting survival. Acta Chirurgica Belgica, 2019, 119, 24-30.	0.2	17
819	A prognostic model based on lymph node metastatic ratio for predicting survival outcome in gastric cancer patients with N3b subclassification. Asian Journal of Surgery, 2019, 42, 85-92.	0.2	14
820	Visceral Fat Area (VFA) Superior to BMI for Predicting Postoperative Complications After Radical Gastrectomy: a Prospective Cohort Study. Journal of Gastrointestinal Surgery, 2020, 24, 1298-1306.	0.9	32
821	Lymph Node Noncompliance Affects the Long-Term Prognosis of Patients with Gastric Cancer after Laparoscopic Total Gastrectomy. Journal of Gastrointestinal Surgery, 2020, 24, 540-550.	0.9	14

#	Article	IF	CITATIONS
822	The Preoperative Prognostic Nutritional Index Predicts Short-Term and Long-Term Outcomes of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-Institution Dataset. Digestive Surgery, 2020, 37, 135-144.	0.6	36
823	Comparative Effectiveness of Lymphadenectomy Strategies During Curative Resection for Gastric Adenocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 2212-2218.	0.9	0
824	The Survival Benefit From the Addition of Radiation to Chemotherapy in Gastric Cancer Patients Following Surgical Resection. Clinical Oncology, 2020, 32, 110-120.	0.6	6
825	Tumor size  ≥50Âmm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative Sâ€1ÂMonotherapy: Analysis of a Multiâ€institution Dataset. World Journal of Surgery, 2020, 44, 194-201.	0.8	4
826	Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 534-542.	0.7	9
827	The Combined Use of Drainage Amylase Concentration and Serum C-reactive Protein as Predictors of Pancreas-Related Complications after Elective Gastrectomy. Oncology, 2020, 98, 111-116.	0.9	6
828	Laparoscopic versus open subtotal gastrectomy for adenocarcinoma of the stomach in a Western population: peri-operative and 5-year oncological outcomes. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 3818-3826.	1.3	5
829	Laparoscopic total gastrectomy for upper-middle advanced gastric cancer: analysis based on lymph node noncompliance. Gastric Cancer, 2020, 23, 184-194.	2.7	15
830	The Clinical Value of Fluorescent Lymphography with Indocyanine Green During Robotic Surgery for Gastric Cancer: a Matched Cohort Study. Journal of Gastrointestinal Surgery, 2020, 24, 2197-2203.	0.9	44
831	Gastric Cancer; Prevention and Treatment. , 2020, , 565-580.		0
832	Radical Gastrectomy: Still the Gold Standard Treatment for Gastric Cancerâ€"Our Experience from a Tertiary Care Center from Northeast India. Indian Journal of Surgical Oncology, 2020, 11, 66-70.	0.3	2
833	Trainee performance in radical gastrectomy and its effect on outcomes. BJS Open, 2020, 4, 86-90.	0.7	5
834	Expanding the indication of endoscopic submucosal dissection for undifferentiated early gastric cancer is safe or not?. Asian Journal of Surgery, 2020, 43, 526-531.	0.2	9
835	Self-reported depression in cancer survivors versus the general population: a population-based propensity score-matching analysis. Quality of Life Research, 2020, 29, 483-494.	1.5	7
837	Prediction scores for complication and recurrence after multivisceral resection in gastric cancer. European Journal of Surgical Oncology, 2020, 46, 1097-1102.	0.5	8
838	Cancer of the Stomach. , 2020, , 1197-1210.e3.		0
839	Sentinel lymph node detection for gastric cancer: Promise or pitfall?. Surgical Oncology, 2020, 33, 1-6.	0.8	17
840	An examination of surgical and survival outcomes in the elderly (65–79 years of age) and the very elderly (≥80 years of age) who received surgery for gastric cancer. Current Medical Research and Opinion, 2020, 36, 229-233.	0.9	9

#	Article	IF	CITATIONS
841	Management following endoscopic resection in elderly patients with earlyâ€stage upper gastrointestinal neoplasia. Digestive Endoscopy, 2020, 32, 861-873.	1.3	27
842	Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer. Cancer, 2020, 126, 1283-1294.	2.0	26
843	Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer, 2020, 23, 550-560.	2.7	21
844	Modified Gastric Cancer AJCC Staging with a Classification Based on the Ratio of Regional Lymph Node Involvement: A Population-Based Cohort Study. Annals of Surgical Oncology, 2020, 27, 1480-1487.	0.7	3
845	Establishment of Decision Rules and Risk Assessment Model for Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer. Frontiers in Oncology, 2020, 10, 1638.	1.3	11
846	The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells. Frontiers in Oncology, 2020, 10, 1608.	1.3	4
847	A novel lymph node staging system for gastric cancer including modified Union for cancer Control/American Joint Committee on cancer and Japanese Gastric Cancer Association criteria. European Journal of Surgical Oncology, 2020, 46, e27-e32.	0.5	5
848	Development and validation of an artificial neural network prognostic model after gastrectomy for gastric carcinoma: An international multicenter cohort study. Cancer Medicine, 2020, 9, 6205-6215.	1.3	13
849	Advances in laparoscopic surgery for the treatment of advanced gastric cancer in China. European Journal of Surgical Oncology, 2020, 46, e7-e13.	0.5	8
850	The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer. Anticancer Research, 2020, 40, 4067-4074.	0.5	8
851	Tumor-infiltrating podoplanin <sup>+</sup> cells in gastric cancer: clinical outcomes and association with immune contexture. Oncolmmunology, 2020, 9, 1845038.	2.1	7
852	Towards Personalization in the Curative Treatment of Gastric Cancer. Frontiers in Oncology, 2020, 10, 614907.	1.3	10
853	Operative and Oncological Outcomes After D2 Versus D1 Gastrectomy of Operable Gastric Cancer: an Observational Study. Journal of Gastrointestinal Cancer, 2022, 53, 91-98.	0.6	3
854	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. Radiotherapy and Oncology, 2020, 152, 19-25.	0.3	9
855	<p>Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis</p> . Cancer Management and Research, 2020, Volume 12, 6641-6653.	0.9	9
856	Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer in middle–low-volume centers in Western countries: a propensity score matching analysis. Langenbeck's Archives of Surgery, 2020, 405, 797-807.	0.8	13
857	Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China. World Journal of Surgical Oncology, 2020, 18, 204.	0.8	24
858	Anterograde "No Touch―Radical Distal Gastrectomy for Gastric Cancer of the Antrum. American Surgeon, 2020, , 000313482094738.	0.4	0

#	Article	IF	CITATIONS
859	Current perspectives on the safety and efficacy of robot-assisted surgery for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1181-1186.	1.4	4
860	A study of outcomes, technical safety, and feasibility of Dâ€2 lymphadenectomy in gastric cancer. JGH Open, 2020, 4, 1114-1118.	0.7	0
861	Targeted Sequencing Analysis of Matched Cell-Free DNA and White Blood Cells: A Facile Method for Detection of Residual Disease in Gastric Cancer. Global Medical Genetics, 2020, 07, 027-029.	0.4	1
863	Prognostic value of total retrieved lymph nodes on the survival of patients with advanced gastric cancer. Journal of the Chinese Medical Association, 2020, 83, 691-692.	0.6	6
864	Gastric cancer. Lancet, The, 2020, 396, 635-648.	6.3	2,084
865	Significance of Lymph Node Resection After Neoadjuvant Therapy in Pancreatic, Gastric, and Rectal Cancers. Annals of Surgery, 2020, 272, 438-446.	2.1	12
866	Postoperative pancreatic fistula after gastrectomy for gastric cancer. Annals of Gastroenterological Surgery, 2020, 4, 618-627.	1.2	19
867	Intratumoral CD103 <sup>+</sup> CD4 <sup>+</sup> T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients. Oncolmmunology, 2020, 9, 1844402.	2.1	14
868	Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node. Technology in Cancer Research and Treatment, 2020, 19, 153303382095940.	0.8	2
869	Mortality calculator as a possible prognostic predictor of overall survival after gastrectomy in elderly patients with gastric cancer. World Journal of Surgical Oncology, 2020, 18, 283.	0.8	3
870	Decreasing resection rates for nonmetastatic gastric cancer in Europe and the United States. Clinical and Translational Medicine, 2020, 10, e203.	1.7	13
871	Extranodal soft tissue metastasis as an independent prognostic factor in gastric cancer patients aged under 70 years after curative gastrectomy. Annals of Translational Medicine, 2020, 8, 376-376.	0.7	2
872	From biology to surgery: One step beyond histology for tailored surgical treatments of gastric cancer. Surgical Oncology, 2020, 34, 86-95.	0.8	4
873	Diffuse gastric cancer: histologic, molecular, and genetic basis of disease. Translational Gastroenterology and Hepatology, 2020, 5, 52-52.	1.5	20
874	Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategiesâ€"a single institution experience. Journal of Gastrointestinal Oncology, 2020, 11, 411-420.	0.6	0
875	Effect of Surgical Approach on Node Harvest in Gastrectomy: Analysis of the National Cancer Database. World Journal of Surgery, 2020, 44, 3061-3069.	0.8	2
876	Gastrectomy with D2 Lymphadenectomy for Carcinoma of the Stomach in a Stand-alone Cancer Centre in Rural India. Indian Journal of Surgical Oncology, 2020, 11, 256-262.	0.3	2
877	Effects of epidural combined with general anesthesia versus general anesthesia alone in gastric cancer surgery: a propensity score matching analysis. Annals of Translational Medicine, 2020, 8, 473-473.	0.7	11

#	Article	IF	CITATIONS
878	The Effectiveness of Gastrectomy With Chemoradiotherapy Among Stage IV Gastric Adenocarcinoma: A Population-Based Analysis. Frontiers in Oncology, 2020, 10, 630.	1.3	5
879	The role of surgery in patients aged 85 years or older with resectable gastric cancer: a propensity score matching analysis of the SEER database. Scandinavian Journal of Gastroenterology, 2020, 55, 694-700.	0.6	5
880	Laparoscopic versus open approach in gastrectomy for advanced gastric cancer: a systematic review. World Journal of Surgical Oncology, 2020, 18, 126.	0.8	17
881	The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer. Surgical Oncology, 2020, 34, 134-139.	0.8	3
882	A nomogram for prediction of stage III/IV gastric cancer outcome after surgery: A multicenter populationâ€based study. Cancer Medicine, 2020, 9, 5490-5499.	1.3	13
883	Functional jejunal interposition versus Roux-en-Y anastomosis after total gastrectomy for gastric cancer: A prospective randomized clinical trial. Surgical Oncology, 2020, 34, 236-244.	0.8	4
884	Multidisciplinary Approach in Improving Survival Outcome of Early-Stage Gastric Cancer. Journal of Surgical Research, 2020, 255, 285-296.	0.8	9
885	Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis. Journal of Cancer, 2020, 11, 4421-4430.	1.2	5
886	The role of bursectomy in the surgical management of gastric cancer: a meta-analysis and systematic review. Updates in Surgery, 2020, 72, 939-950.	0.9	3
887	Oncologic and surgical outcomes for gastric cancer patients undergoing gastrectomy differ by race in the United States. European Journal of Surgical Oncology, 2020, 46, 1941-1947.	0.5	11
888	Surgical Outcome and Long-Term Survival of Conversion Surgery for Advanced Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 4250-4260.	0.7	17
889	Global updates in the treatment of gastric cancer: a systematic review. Part 1: staging, classification and surgical treatment. Updates in Surgery, 2020, 72, 341-353.	0.9	23
890	Intraoperative Surrogate Indicators of Gastric Cancer Patients' Long-Term Prognosis: The Number of Lymph Nodes Examined Relates to the Lymph Node Noncompliance Rate. Annals of Surgical Oncology, 2020, 27, 3281-3293.	0.7	10
891	Surgery for Gastric Cancer: State of the Art. Indian Journal of Surgery, 2020, , 1.	0.2	1
892	Poor clinical outcomes of intratumoral dendritic cell–specific intercellular adhesion molecule 3–grabbing non-integrin–positive macrophages associated with immune evasion in gastric cancer. European Journal of Cancer, 2020, 128, 27-37.	1.3	28
893	A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. European Journal of Cancer, 2020, 130, 23-31.	1.3	40
894	Nationwide study of the impact of D2 lymphadenectomy on survival after gastric cancer surgery. BJS Open, 2020, 4, 424-431.	0.7	6
895	CD66b <sup>+</sup> neutrophils and αâ€SMA <sup>+</sup> fibroblasts predict clinical outcomes and benefits from postoperative chemotherapy in gastric adenocarcinoma. Cancer Medicine, 2020, 9, 2761-2773.	1.3	15

#	Article	IF	CITATIONS
896	Safety and Efficacy of Indocyanine Green Tracer-Guided Lymph Node Dissection During Laparoscopic Radical Gastrectomy in Patients With Gastric Cancer. JAMA Surgery, 2020, 155, 300.	2.2	178
897	Clinicopathologic Features, Survival Outcome, and Prognostic Factors in Gastric Cancer Patients 18–40 Years of Age. Journal of Adolescent and Young Adult Oncology, 2020, 9, 514-521.	0.7	6
898	Surgical margins in gastric cancer T2 and T3 and its relationship with recurrence and overall survival at 5 years. Surgical Oncology, 2020, 34, 13-16.	0.8	1
899	Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates in Surgery, 2020, 72, 1-19.	0.9	2
901	Challenges in the treatment of gastric cancer in the older patient. Cancer Treatment Reviews, 2020, 85, 101980.	3.4	76
902	Fatty acid synthase is a prognostic marker and associated with immune infiltrating in gastric cancers precision medicine. Biomarkers in Medicine, 2020, 14, 185-199.	0.6	15
903	A SEER population analysis of stage IB resected gastric cancer: who can benefit from adjuvant therapy?. Scandinavian Journal of Gastroenterology, 2020, 55, 193-201.	0.6	2
904	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, 11, 525.	5.8	158
905	Incidence of Multiple Metachronous Gastric Cancers After Pyloricâ€Preserving Gastrectomy. World Journal of Surgery, 2020, 44, 2719-2727.	0.8	4
906	Prevalence and risk factors for lymph node metastasis after noncurative endoscopic resection for early gastric cancer: a systematic review and meta-analysis. Journal of Gastroenterology, 2020, 55, 742-753.	2.3	17
907	Management of Gastric Adenocarcinoma for General Surgeons. Surgical Clinics of North America, 2020, 100, 523-534.	0.5	20
908	Multicenter Validation Study of the American Joint Commission on Cancer (8th Edition) for Gastric Cancer: Proposal for a Simplified and Improved TNM Staging System. Journal of Cancer, 2020, 11, 3483-3491.	1.2	10
909	Significance of nodal dissection and nodal positivity in gastric cancer. Translational Gastroenterology and Hepatology, 2020, 5, 17-17.	1.5	12
910	Therapeutic value of splenectomy to dissect splenic hilar lymph nodes for type 4 gastric cancer involving the greater curvature, compared with other types. Gastric Cancer, 2020, 23, 927-936.	2.7	10
911	Comparison of long term survival outcomes between D1+ and D2 lymph node dissection for ≥ pT2 or pN+ gastric carcinoma: A large scale case-control study using propensity score matching. European Journal of Surgical Oncology, 2020, 46, 1239-1246.	0.5	4
912	Outcomes of Gastric Resection in the Establishment of a Comprehensive Oncologic Robotic Program. Journal of Surgical Research, 2020, 252, 30-36.	0.8	1
913	Risk Factors for Duodenal Stump Leakage after Laparoscopic Gastrectomy for Gastric Cancer. Journal of Gastric Cancer, 2020, 20, 81.	0.9	8
914	Trimodality therapy for resectable gastric cancer: analysis of the benefit in radiation. International Journal of Surgery Oncology, 2021, 2, 06.	0.2	0

#	Article	IF	CITATIONS
915	The principles of the surgical management of gastric cancer. International Journal of Surgery Oncology, 2017, 2, e11-e11.	0.2	17
916	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori, 2021, 107, 150-159.	0.6	8
917	Clinical Outcomes and Prognostic Factors in Gastric Carcinoma Patients with Curative Surgery Followed by Adjuvant Treatment: Real-World Scenario. Journal of Gastrointestinal Cancer, 2021, 52, 616-624.	0.6	0
918	Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China. Surgery Today, 2021, 51, 101-110.	0.7	20
919	The assessment of the optimal number of examined lymph nodes and prognostic models based on lymph nodes for predicting survival outcome in patients with stage N3b gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e117-e124.	0.7	7
920	Oncologic feasibility of D1+ gastrectomy for patients with cT1N1, cT2N0-1, or cT3N0 gastric cancer. European Journal of Surgical Oncology, 2021, 47, 456-462.	0.5	2
921	Adjuvant radiotherapy for gastric cancerâ€"end of the road?. Annals of Oncology, 2021, 32, 287-289.	0.6	16
922	Challenges to quality assurance of surgical interventions in clinical oncology trials: A systematic review. European Journal of Surgical Oncology, 2021, 47, 748-756.	0.5	6
923	Lymphadenectomy for gastric cancer at European specialist centres. European Journal of Surgical Oncology, 2021, 47, 1048-1054.	0.5	5
924	A qualitative classification signature for post-surgery 5-fluorouracil-based adjuvant chemoradiotherapy in gastric cancer. Radiotherapy and Oncology, 2021, 155, 65-72.	0.3	3
925	The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China. Surgery, 2021, 169, 426-435.	1.0	4
926	Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer, 2021, 52, 41-56.	0.6	13
927	Assessment of diagnostic value of fluorescent lymphography-guided lymphadenectomy for gastric cancer. Gastric Cancer, 2021, 24, 515-525.	2.7	24
928	Magenkarzinom. , 2021, , 94-102.		O
929	Pancreatic Fistula after D1+/D2 Radical Gastrectomy according to the Updated International Study Group of Pancreatic Surgery Criteria: Risk Factors and Clinical Consequences. Experience of Surgeons with High Caseloads in a Single Surgical Center in Eastern Europe. Journal of Gastric Cancer, 2021, 21, 16.	0.9	4
930	Laparoscopic surgery for gastric cancer: Current status and future direction. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 133-141.	0.7	5
931	Gastric equivalent of the †Holy Plane' to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson's historic schema. Gastric Cancer, 2021, 24, 273-282.	2.7	12
932	Maag en duodenum. , 2021, , 177-191.		0

#	Article	IF	CITATIONS
933	Evaluating quality and completeness of gastrectomy for gastric cancer: review of surgical videos from the public domain. Translational Gastroenterology and Hepatology, 2021, 6, 57-57.	1.5	2
934	ICGâ€NIRâ€guided lymph node dissection during robotic subtotal gastrectomy for gastric cancer. A singleâ€centre experience. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2213.	1.2	16
935	Relationship Between Postoperative Complications and the Prognosis of Gastric Carcinoma Patients Who Underwent Surgical Resection: A Systematic Review and Meta-Analysis. Cancer Control, 2021, 28, 107327482110119.	0.7	14
936	Minimally invasive gastrectomy after neoadjuvant chemotherapy: a literature review. Annals of Laparoscopic and Endoscopic Surgery, 0, 7, 10-10.	0.5	O
937	The efficiency of D1(+) lymphadenectomy in signet ring cell carcinoma: comparison of postoperative early and late outcomes between standard lymphadenectomy and D1(+) lymphadenectomy. Libyan Journal of Medicine, 2021, 16, 1973761.	0.8	3
938	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. Oncolmmunology, 2021, 10, 1915560.	2.1	17
939	Applications of Decellularized Materials for Tissue Repair. , 2021, , 181-251.		0
940	Primary tumor resection benefited the survival of patients with distant metastatic gastric cancer. Journal of Research in Medical Sciences, 2021, 26, 24.	0.4	2
941	Importance of Examined Lymph Node Number in Accurate Staging and Enhanced Survival in Resected Gastric Adenocarcinomaâ€"The More, the Better? A Cohort Study of 8,696 Cases From the US and China, 2010â€"2016. Frontiers in Oncology, 2020, 10, 539030.	1.3	11
942	Current status and future perspectives on neoadjuvant therapy in gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 181-192.	0.7	8
943	BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 2): UPDATE ON TREATMENT. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2021, 34, e1563.	0.5	12
944	Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study. Tzu Chi Medical Journal, 2021, 33, 288.	0.4	O
945	Advances in the surgical management of gastric and gastroesophageal junction cancer. Translational Gastroenterology and Hepatology, 2021, 6, 16-16.	1.5	6
946	Appraisal of long-time outcomes after curative surgery in elderly patients with gastric cancer: a propensity score matching analysis. BMC Surgery, 2021, 21, 33.	0.6	8
947	A Randomized Phase II Study to Evaluate Prolonged Prophylactic Antibacterial Drug Treatment for Patients with Elevated Drain Amylase Concentration After Gastrectomy with D2ÂLymph Node Dissection (REDUCED2). World Journal of Surgery, 2021, 45, 1135-1143.	0.8	1
948	Robot-assisted laparoscopic subtotal gastrectomy for early-stage gastric cancer: Case series of initial experience. Annals of Medicine and Surgery, 2021, 61, 115-121.	0.5	0
949	Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers, 2021, 13, 582.	1.7	22
950	Incidence of adhesive small bowel obstruction after gastrectomy for gastric cancer and its risk factors: a long-term retrospective cohort study from a high-volume institution in China. Updates in Surgery, 2021, 73, 615-626.	0.9	8

#	ARTICLE	IF	CITATIONS
952	The 140Âyears' journey of gastric cancer surgery: From the two hands of Billroth to the multiple hands of the robot. Annals of Gastroenterological Surgery, 2021, 5, 270-277.	1.2	11
953	Comment on "Textbook Outcome and Survival in Patients With Gastric Cancer: An Analysis of the Population Registry of Esophageal and Stomach Tumors in Ontario (PRESTO)â€. Annals of Surgery, 2021, 274, e885-e886.	2.1	1
954	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience, 2021, 15, 1195.	0.6	1
955	Impact of the introduction of formal D2 lymphadenectomy for gastric cancer in a Western setting. Canadian Journal of Surgery, 2021, 64, E119-E126.	0.5	3
956	Factores de riesgo asociados con morbilidad y mortalidad postoperatoria en gastrectomÃa radical D2 por cáncer gástrico. Revista De GastroenterologÃa De México, 2021, , .	0.4	1
957	Effect of Preoperative Tumour Under-Staging on the Long-Term Survival of Patients Undergoing Radical Gastrectomy for Gastric Cancer. Cancer Research and Treatment, 2021, 53, 1123-1133.	1.3	2
958	Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Annals of Oncology, 2021, 32, 360-367.	0.6	40
959	Treatment approach, hospital practice patterns, and receipt of multimodality therapy as measures of quality for locally advanced gastric cancer. Journal of Surgical Oncology, 2021, 123, 1724-1735.	0.8	4
960	Perioperative outcomes and survival in elderly patients aged ≥ 75Âyears undergoing gastrectomy for gastric cancer: an 18-year retrospective analysis in a single Western centre. Langenbeck's Archives of Surgery, 2021, 406, 1057-1069.	0.8	3
961	Isolated brachioradialis metastasis of gastric adenocarcinoma after RO resection. World Journal of Surgical Oncology, 2021, 19, 83.	0.8	0
962	The development and external validation of a nomogram predicting overall survival of gastric cancer patients with inadequate lymph nodes based on an international database. International Journal of Clinical Oncology, 2021, 26, 867-874.	1.0	1
963	Lymph Node Mapping in Gastric Carcinoma. Journal of Gastrointestinal and Abdominal Radiology, 0, , .	0.2	3
964	Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. Journal of Gastrointestinal Oncology, 2021, 12, S5-S17.	0.6	7
965	Current status of extended  D2 plus' lymphadenectomy in advanced gastric cancer (Review). Oncology Letters, 2021, 21, 467.	0.8	4
966	Laparoscopic infrapyloric lymph nodes dissection through the right bursa omentalis approach for gastric cancer. BMC Surgery, 2021, 21, 216.	0.6	0
967	Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer. Journal of Gastrointestinal Oncology, 2021, 12, S47-S56.	0.6	4
968	Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience. World Journal of Surgical Oncology, 2021, 19, 124.	0.8	9
969	Adverse Prognostic Impact of Postoperative Complications After Gastrectomy for Patients With Stage II/III Gastric Cancer: Analysis of Prospectively Collected Real-World Data. Frontiers in Oncology, 2021, 11, 611510.	1.3	8

#	Article	IF	CITATIONS
970	Retrospective Evaluation of Factors Affecting Lymph Node Retrieval Following Gastrectomies with Oncologic Intent. Rambam Maimonides Medical Journal, 2021, 12, e0012.	0.4	0
971	Maintenance in gastric cancer: New life for an old issue?. Critical Reviews in Oncology/Hematology, 2021, 160, 103307.	2.0	4
972	Robotic versus laparoscopic distal gastrectomy in patients with gastric cancer: a propensity score-matched analysis. BMC Surgery, 2021, 21, 203.	0.6	13
973	Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatmentâ€"Oncological and Surgical Perspective. Cancers, 2021, 13, 2509.	1.7	11
974	Ultrastaging Using Ex Vivo Sentinel Lymph Node Mapping and One-Step Nucleic Acid Amplification (OSNA) in Gastric Cancer: Experiences of a European Center. Cancers, 2021, 13, 2683.	1.7	3
975	Registrar performance in minimally invasive distal pancreatectomy and effects on postoperative outcomes. Langenbeck's Archives of Surgery, 2021, 406, 2357-2365.	0.8	0
976	Hospitalâ€level compliance with the commission on cancer's quality of care measures and the association with patient survival. Cancer Medicine, 2021, 10, 3533-3544.	1.3	2
977	Surgical Management of Gastric Cancer: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 2557.	1.0	22
978	D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial. European Journal of Cancer, 2021, 150, 10-22.	1.3	30
980	Potential survival benefits of open over laparoscopic radical gastrectomy for gastric cancer patients beyond three years after surgery: result from multicenter in-depth analysis based on propensity matching. Surgical Endoscopy and Other Interventional Techniques, 2021, , 1.	1.3	5
981	Prognostic Value of Pretreatment Overweight/Obesity and Adipose Tissue Distribution in Resectable Gastric Cancer: A Retrospective Cohort Study. Frontiers in Oncology, 2021, 11, 680190.	1.3	5
982	GASTRIC CANCER: A 5 YEAR RETROSPECTIVE ANALYSIS OF CLINICAL, PATHOLOGICAL AND TREATMENT ASPECTS FROM A TERTIARY CARE CENTER IN SOUTH INDIA , 2021, , 129-132.		0
983	Surgical approaches for retroperitoneal tumors. Surgery in Practice and Science, 2021, 5, 100032.	0.2	1
984	Surgical Treatment for Gastric Cancer. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 581-605.	0.6	9
985	Institutional variation in survival and morbidity in laparoscopic surgery for colon cancer: From the data of a randomized controlled trial comparing open and laparoscopic surgery (JCOG0404). Annals of Gastroenterological Surgery, 2021, 5, 823-831.	1.2	5
986	Robotic Gastrectomy Versus Laparoscopic Gastrectomy for Gastric Cancer. Annals of Surgery, 2023, 277, e87-e95.	2.1	37
987	Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer. JAMA Network Open, 2021, 4, e2116240.	2.8	25
988	Pathological N3 Stage (pN3/ypN3) Gastric Cancer: Outcomes, Prognostic Factors and Pattern of Recurrences After Curative Treatment. Annals of Surgical Oncology, 2021, , 1.	0.7	6

#	Article	IF	CITATIONS
989	Remission of type 2 diabetes after gastrectomy for gastric cancer: diabetes prediction score. Gastric Cancer, 2022, 25, 265-274.	2.7	6
990	Advances in Systemic Therapy for Gastric Cancer. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 607-623.	0.6	11
991	Clinical Significance of Metastasis or Micrometastasis to the Lymph Node Along the Superior Mesenteric Vein in Gastric Carcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 707249.	1.3	2
992	Shifting sands: the role of radiotherapy for patients with gastric and gastroesophageal adenocarcinoma. Translational Gastroenterology and Hepatology, 2021, 6, 50-50.	1.5	1
993	Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression. World Journal of Surgical Oncology, 2021, 19, 205.	0.8	4
994	Avalia $ ilde{A}$ § $ ilde{A}$ £o da qualidade de vida de adolescentes em tratamento de c $ ilde{A}$ ¢ncer: Uma revis $ ilde{A}$ £o integrativa. Research, Society and Development, 2021, 10, e42310817392.	0.0	0
996	Evolution of gastrectomy for cancer over 30-years: Changes in presentation, management, and outcomes. Surgery, 2021, 170, 2-10.	1.0	9
997	Molecularly Targeted Therapies for Gastric Cancer. State of the Art. Cancers, 2021, 13, 4094.	1.7	10
998	Safety and Efficacy of Laparoscopic Versus Open Gastrectomy in Patients With Advanced Gastric Cancer Following Neoadjuvant Chemotherapy: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 704244.	1.3	11
999	Recanalization in Uncut Roux-en-Y Reconstruction: An Animal Experiment and a Clinical Study. Frontiers in Surgery, 2021, 8, 644864.	0.6	10
1000	Exocrine pancreatic insufficiency in long-term follow-up after curative gastric resection with D2 lymphadenectomy: A cross-sectional study. Pancreatology, 2021, 21, 975-982.	0.5	5
1001	Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer, 2022, 25, 22-32.	2.7	15
1002	Central vascular ligation and mesentery based abdominal surgery. Discover Oncology, 2021, 12, 24.	0.8	2
1003	Risk factors associated with postoperative morbidity and mortality in D2 radical gastrectomy for gastric cancer. Revista De GastroenterologÃa De MÁ©xico (English Edition), 2022, 87, 149-158.	0.1	3
1004	Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas. Cancers, 2021, 13, 3894.	1.7	9
1005	Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: a propensity score matched analysis. Journal of Gastrointestinal Oncology, 2021, 12, 1308-1325.	0.6	4
1006	Lack of Oncological Benefit from Bursectomy in Radical Gastrectomy: A Systematic Review. Visceral Medicine, 2021, 37, 511-520.	0.5	2
1007	Treatment burden of robotic gastrectomy for locally advanced gastric cancer (LAGC): a single western experience. Annals of Translational Medicine, 2021, 9, 1408-1408.	0.7	1

#	Article	IF	CITATIONS
1008	Stroma <scp>A</scp> Reactive <scp>I</scp> nvasion <scp>F</scp> ront <scp>A</scp> reas ( <scp>SARIFA</scp> ) â€" a new prognostic biomarker in gastric cancer related to tumorâ€promoting adipocytes. Journal of Pathology, 2022, 256, 71-82.	2.1	11
1009	Prognostic significance of surgeryâ€induced sarcopenia in the survival of gastric cancer patients: a sexâ€specific analysis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1897-1907.	2.9	22
1010	Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy?. Frontiers in Oncology, 2021, 11, 709617.	1.3	3
1011	ASO Visual Abstract: Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 734-735.	0.7	5
1012	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 1220-1229.	0.7	8
1013	Systematic review and updated network meta-analysis of randomized controlled trials comparing open, laparoscopic-assisted, and robotic distal gastrectomy for early and locally advanced gastric cancer. Surgery, 2021, 170, 942-951.	1.0	20
1014	Value of preoperative gastroscopic carbon nanoparticles labeling in patients undergoing laparoscopic radical gastric cancer surgery. Surgical Oncology, 2021, 38, 101628.	0.8	12
1015	Indocyanine green imaging to guide lymphadenectomy in laparoscopic distal gastrectomy - With vÃdeo. Annals of Medicine and Surgery, 2021, 69, 102657.	0.5	0
1016	Lymph node dissection for gastric cancer: Establishment of D2 and the current position of splenectomy in Europe and Japan. European Journal of Surgical Oncology, 2021, 47, 2233-2236.	0.5	9
1017	Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review. Surgical Oncology, 2021, 38, 101599.	0.8	3
1018	Safety and efficacy of indocyanine green fluorescence imaging-guided radical gastrectomy: a systematic review and meta-analysis. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1319-1328.	1.4	7
1019	Efficacy and Safety of Additional S-1 Chemotherapy to S-1 plus Oxaliplatin Regimen Chemotherapy for Stage III Gastric Carcinoma after Radical Resection. Cancer Investigation, 2021, , 1-11.	0.6	1
1021	Pattern of No. 12a lymph node metastasis in gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 61-68.	0.7	1
1022	Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Annals of Surgical Oncology, 2021, 28, 4433-4443.	0.7	4
1023	Optimal Timing to Assess Drain Amylase Concentration after Elective Gastrectomy. Journal of Gastric Cancer, 2021, 21, 30.	0.9	1
1024	Central lymph node metastasis is predictive of survival in advanced gastric cancer patients treated with D2 lymphadenectomy. BMC Gastroenterology, 2021, 21, 15.	0.8	6
1025	Immune gene prognostic signature for disease free survival of gastric cancer: Translational research of an artificial intelligence survival predictive system. Computational and Structural Biotechnology Journal, 2021, 19, 2329-2346.	1.9	5
1026	Surgical treatment of gastric cancer: Current status and future directions. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 159-167.	0.7	18

#	Article	IF	CITATIONS
1027	Conditional survival of patients with gastric cancer who undergo curative resection: A multiâ€institutional analysis in China. Cancer, 2018, 124, 916-924.	2.0	28
1028	Robotic Utilization in Gastric Cancer Surgery. , 2015, , 261-268.		2
1029	Importance of Adequate Lymphadenectomy in Gastrointestinal Cancer. Cancer Treatment and Research, 2016, 168, 331-343.	0.2	2
1030	Can Adjuvant Chemoradiotherapy Replace Extended Lymph Node Dissection in Gastric Cancer?. Recent Results in Cancer Research, 2012, 196, 229-240.	1.8	6
1031	Adjuvant Chemotherapy: An Option for Asian Patients Only?. Recent Results in Cancer Research, 2012, 196, 291-305.	1.8	2
1032	Prognostic Factors and Score Systems in Gastric Cancer. , 2012, , 35-42.		2
1033	Is the eCura system useful for selecting patients who require radical surgery after noncurative endoscopic submucosal dissection for early gastric cancer? A comparative study. Gastric Cancer, 2018, 21, 481-489.	2.7	51
1034	Delaying adjuvant chemotherapy in advanced gastric cancer patients: Risk factors and its impact on survival outcome. Current Problems in Cancer, 2020, 44, 100577.	1.0	6
1036	Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics. Bioengineered, 2021, 12, 127-137.	1.4	38
1037	Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients. Annals of Surgery, 2022, 275, e626-e635.	2.1	95
1038	Correlations of Hemoglobin Level and Perioperative Blood Transfusion with the Prognosis of Gastric Cancer: A Retrospective Study. Medical Science Monitor, 2017, 23, 2470-2478.	0.5	13
1039	Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A Review. Medical Science Monitor, 2019, 25, 3537-3541.	0.5	262
1040	New metastatic lymph node classification for early gastric cancer should differ from those for advanced gastric adenocarcinoma: Results based on the SEER database. World Journal of Clinical Cases, 2019, 7, 145-155.	0.3	4
1041	Effect of Lymph Node Number on Survival of Patients with Lymph Node-Negative Gastric Cancer according to the 7th Edition UICC TNM System. PLoS ONE, 2012, 7, e38681.	1.1	46
1042	Efficacy Evaluation of Subtotal and Total Gastrectomies in Robotic Surgery for Gastric Cancer Compared with that in Open and Laparoscopic Resections: A Meta-Analysis. PLoS ONE, 2014, 9, e103312.	1.1	48
1043	Comparison of Ultrasonic Scalpel versus Conventional Techniques in Open Gastrectomy for Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e103330.	1.1	7
1044	A Lymph Node Staging System for Gastric Cancer: A Hybrid Type Based on Topographic and Numeric Systems. PLoS ONE, 2016, 11, e0149555.	1.1	24
1045	Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS ONE, 2017, 12, e0186362.	1.1	15

#	Article	IF	CITATIONS
1046	Adequacies of lymphadenectomy range for gastric cancer according to the second and third/fourth Japanese gastric cancer treatment guidelines. Korean Journal of Clinical Oncology, 2017, 13, 62-67.	0.1	3
1047	Comparison of long-term oncologic outcomes of laparoscopic gastrectomy and open gastrectomy for advanced gastric cancer: A retrospective cohort study. Korean Journal of Clinical Oncology, 2018, 14, 21-29.	0.1	2
1048	Disparities in the Diagnosis and Treatment of Gastric Cancer in Relation to Disabilities. Clinical and Translational Gastroenterology, 2020, 11, e00242.	1.3	11
1050	ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2019, 32, e1464.	0.5	3
1051	Clinicopathologic factors associated with recurrence and long-term survival in node-negative advanced gastric cancer patients. Revista Espanola De Enfermedades Digestivas, 2018, 111, 111-120.	0.1	11
1052	The predictive factors of gastric cancer recurrence after the completion of adjuvant chemotherapy in advanced gastric cancer. Revista Espanola De Enfermedades Digestivas, 2019, 111, 537-542.	0.1	10
1053	A novel grade-lymph node ratio model predicts the prognosis of the advanced gastric cancer patients after neoadjuvant radiotherapy. Oncotarget, 2017, 8, 14058-14067.	0.8	4
1054	The comprehensive therapeutic effects of rectal surgery are better in laparoscopy: a systematic review and meta-analysis. Oncotarget, 2017, 8, 12717-12729.	0.8	24
1055	Nomogram analysis and external validation to predict the risk of lymph node metastasis in gastric cancer. Oncotarget, 2017, 8, 11380-11388.	0.8	14
1056	Lymph nodes ratio based nomogram predicts survival of resectable gastric cancer regardless of the number of examined lymph nodes. Oncotarget, 2017, 8, 45585-45596.	0.8	12
1057	Effect of postoperative analgesia technique on the prognosis of gastric cancer: a retrospective analysis. Oncotarget, 2017, 8, 104594-104604.	0.8	13
1058	Integrated multigene expression panel to prognosticate patients with gastric cancer. Oncotarget, 2018, 9, 18775-18785.	0.8	8
1059	The role of different adjuvant therapies in locally advanced gastric adenocarcinoma. Oncotarget, 2018, 9, 34022-34029.	0.8	6
1060	The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy. Oncotarget, 2016, 7, 18750-18762.	0.8	8
1061	Strategies to improve treatment outcome in gastric cancer: A retrospective analysis of patients from two high-volume hospitals in Korea and China. Oncotarget, 2016, 7, 44660-44675.	0.8	21
1063	Gastric cancer surgery: historical background and perspective in Western countries versus Japan. Annals of Translational Medicine, 2019, 7, 493-493.	0.7	21
1064	Development and validation of prognostic nomogram for young patients with gastric cancer. Annals of Translational Medicine, 2019, 7, 641-641.	0.7	69
1065	Ongoing clinical studies of minimally invasive surgery for gastric cancer in Japan. Translational Gastroenterology and Hepatology, 2016, 1, 31-31.	1.5	7

#	Article	IF	CITATIONS
1066	Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 397-403.	0.7	15
1067	Comparison of lymph node number and prognosis in gastric cancer patients with perigastric lymph nodes retrieved by surgeons and pathologists. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 511-518.	0.7	20
1068	Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 100-108.	0.7	4
1069	Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in Sweden. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 313-322.	0.7	4
1070	Validation of clinical significance of examined lymph node count for accurate prognostic evaluation of gastric cancer for the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 477-491.	0.7	34
1071	Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer. Anticancer Research, 2017, 37, 3061-3067.	0.5	5
1072	Advanced gastric cancer: the value of surgery. Acta Biomedica, 2018, 89, 110-116.	0.2	16
1073	Gastric canceractual multimodality treatment strategies. Polski Przeglad Chirurgiczny, 2012, 84, 461-9.	0.2	1
1074	Update on the Treatment of Gastric Cancer. JMA Journal, 2018, 1, 40-49.	0.6	22
1075	Neutrophil-lymphocyte ratio change after curative gastrectomy for gastric cancer: a subgroup analysis. Einstein (Sao Paulo, Brazil), 2019, 18, eAO4860.	0.3	5
1076	Treatment Strategies in Gastric Cancer. Deutsches Ärzteblatt International, 2011, 108, 698-705; quiz 706.	0.6	64
1077	Determinants of surgical morbidity in gastric cancer: experience of a single center and literature review. Journal of Gastric Surgery, 2020, 2, Press.	0.2	1
1078	Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection. World Journal of Gastroenterology, 2013, 19, 1975.	1.4	28
1079	Chemotherapy and resection for gastric cancer with synchronous liver metastases. World Journal of Gastroenterology, 2013, 19, 2097.	1.4	39
1080	Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World Journal of Gastroenterology, 2013, 19, 3309.	1.4	12
1081	Impact of being overweight on the surgical outcomes of patients with gastric cancer: A meta-analysis. World Journal of Gastroenterology, 2013, 19, 4596-4606.	1.4	54
1082	Impact of intraoperative blood loss on survival after curative resection for gastric cancer. World Journal of Gastroenterology, 2013, 19, 5542.	1.4	58
1083	Characteristics and prognosis of gastric cancer in patients aged ≥ 70 years. World Journal of Gastroenterology, 2013, 19, 6568.	1.4	74

#	Article	IF	Citations
1084	Digestive cancer surgery in the era of sentinel node and epithelial-mesenchymal transition. World Journal of Gastroenterology, 2013, 19, 8996.	1.4	7
1085	Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. World Journal of Gastroenterology, 2014, 20, 3356.	1.4	1
1086	Extent of lymphadenectomy and perioperative therapies: Two open issues in gastric cancer. World Journal of Gastroenterology, 2014, 20, 3889.	1.4	16
1087	Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. World Journal of Gastroenterology, 2014, 20, 4516.	1.4	30
1088	Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?. World Journal of Gastroenterology, 2014, 20, 6981.	1.4	9
1089	Effect of complication grade on survival following curative gastrectomy for carcinoma. World Journal of Gastroenterology, 2014, 20, 8244.	1.4	49
1090	Racial and ethnic disparities in gastric cancer outcomes: More important than surgical technique?. World Journal of Gastroenterology, 2014, 20, 11546.	1.4	31
1091	Towards personalized perioperative treatment for advanced gastric cancer. World Journal of Gastroenterology, 2014, 20, 11586.	1.4	25
1092	Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer. World Journal of Gastroenterology, 2014, 20, 12883.	1.4	36
1093	Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects. World Journal of Gastroenterology, 2014, 20, 12892.	1.4	17
1094	Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?. World Journal of Gastroenterology, 2014, 20, 12900.	1.4	7
1095	Comparison of different gastric bypass procedures in gastric carcinoma patients with type 2 diabetes mellitus. World Journal of Gastroenterology, 2014, 20, 18427.	1.4	5
1096	Adjuvant therapy for gastric cancer: What have we learned since INTO116?. World Journal of Gastroenterology, 2015, 21, 3850.	1.4	13
1097	Clinical characteristics of hepatoduodenal lymph node metastasis in gastric cancer. World Journal of Gastroenterology, 2015, 21, 10866.	1.4	2
1098	Towards curative therapy in gastric cancer: Faraway, so close!. World Journal of Gastroenterology, 2015, 21, 11609.	1.4	12
1099	Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World Journal of Gastroenterology, 2015, 21, 13294.	1.4	10
1100	Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer. World Journal of Gastroenterology, 2015, 21, 13500.	1.4	15
1101	Minimally invasive surgery for upper gastrointestinal cancer: Our experience and review of the literature. World Journal of Gastroenterology, 2016, 22, 4626.	1.4	34

#	Article	IF	CITATIONS
1102	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World Journal of Gastroenterology, 2016, 22, 1114.	1.4	75
1103	Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?. World Journal of Gastroenterology, 2016, 22, 1131.	1.4	8
1104	Advanced gastric cancer: What we know and what we still have to learn. World Journal of Gastroenterology, 2016, 22, 1139.	1.4	59
1105	Personalized medicine in gastric cancer: Where are we and where are we going?. World Journal of Gastroenterology, 2016, 22, 1160.	1.4	37
1106	Prediction of lymph node metastasis and sentinel node navigation surgery for patients with early-stage gastric cancer. World Journal of Gastroenterology, 2016, 22, 7431.	1.4	14
1107	Predictive factors for body weight loss and its impact on quality of life following gastrectomy. World Journal of Gastroenterology, 2017, 23, 4823.	1.4	20
1108	Retrospective analysis of treatment outcomes after postoperative chemoradiotherapy in advanced gastric cancer. Radiation Oncology Journal, 2011, 29, 252.	0.7	10
1109	Surgical management of gastric cancer: the East vs. West perspective. Journal of Gastrointestinal Oncology, 2015, 6, 79-88.	0.6	38
1110	Emerging role of S-1 in gastric cancer. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 219-228.	0.1	5
1111	Oncologic value of laparoscopy-assisted distal gastrectomy for advanced gastric cancer: A systematic review and meta-analysis. Journal of Minimal Access Surgery, 2016, 12, 199.	0.4	12
1112	Radical gastrectomy for gastric cancer at Tata Memorial Hospital. Indian Journal of Cancer, 2017, 54, 605.	0.2	7
1113	Inhibition of the hypoxia-induced factor- $\hat{l}$ ± and vascular endothelial growth factor expression through ginsenoside Rg3 in human gastric cancer cells. Journal of Cancer Research and Therapeutics, 2019, 15, 1642.	0.3	15
1114	Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. Journal of Pathology and Translational Medicine, 2016, 50, 1-9.	0.4	21
1115	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node–Positive Gastric Cancer Treated with Different Adjuvant Protocols. Cancer Research and Treatment, 2019, 51, 876-885.	1.3	8
1116	Parametric Cure Model versus Proportional Hazards Model in Survival Analysis of Breast Cancer and Other Malignancies. Advances in Breast Cancer Research, 2013, 02, 119-125.	0.1	7
1117	Sentinel node navigation surgery for gastric cancer: Overview and perspective. World Journal of Gastrointestinal Surgery, 2015, 7, 1.	0.8	28
1118	Advancements and challenges in treating advanced gastric cancer in the West. World Journal of Gastrointestinal Oncology, 2019, 11, 652-664.	0.8	25
1119	Current status of adjuvant chemotherapy for gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 679-687.	0.8	20

#	Article	IF	CITATIONS
1120	Robot-assisted laparoscopic gastrectomy for gastric cancer. World Journal of Gastrointestinal Endoscopy, 2017, 9, 1.	0.4	10
1121	Changing Trends in Gastric Cancer Surgery. Balkan Medical Journal, 2017, 34, 10-20.	0.3	12
1122	Detection and clinical significance of DNA repair gene ERCC8 tag SNPs in gastric cancer. Turkish Journal of Gastroenterology, 2018, 29, 392-396.	0.4	3
1123	Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group. Turkish Journal of Gastroenterology, 2019, 30, 584-598.	0.4	4
1124	Survival outcomes after D1 and D2 lymphadenectomy with R0 resection in stage Il–III gastric cancer: Longitudinal follow-up in a single center. Turkish Journal of Surgery, 2018, 34, 125-130.	0.1	7
1125	D1 versus D2 dissection in stomach carcinoma: evaluation of postoperative mortality and complications. Turkish Journal of Surgery, 2013, 29, 1-6.	1.0	9
1126	Robot-assisted laparoscopic vs open gastrectomy for gastric cancer: Systematic review and meta-analysis. World Journal of Clinical Oncology, 2017, 8, 273.	0.9	20
1127	Tumor volume of resectable gastric adenocarcinoma on multidetector computed tomography: association with N categories. Clinics, 2016, 71, 199-204.	0.6	7
1128	Adjuvant Radiotherapy for Gastric Carcinoma: 10 years Follow-up of 244 cases from a Single Institution. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8871-8876.	0.5	4
1129	Mortality and Morbidity and Disease Free Survival after D1 and D2 Gastrectomy for Stomach Adenocarcinomas. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5253-5256.	0.5	3
1130	Presentation and Outcomes of Gastric Cancer at a University Teaching Hospital in Nepal. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5385-5388.	0.5	6
1131	Comparison of Ligasure Versus Conventional Surgery for Curative Gastric Cancer Resection: a Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2016, 17, 2049-2053.	0.5	6
1132	Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biology and Medicine, 2015, 12, 284-91.	1.4	5
1133	Laparoscopic Versus Open Distal Gastrectomy With D2 Lymph Node Dissection for cT2 Gastric Cancer: A Retrospective Cohort Study of Short- and Long-Term Outcomes. International Surgery, 2015, 100, 1315-1322.	0.0	2
1134	Surgical Navigation in Gastric Cancer. Updates in Surgery Series, 2021, , 213-217.	0.0	0
1136	Impact of Hospital and Surgeon Volume on the Outcomes of Gastric Cancer Surgery. Updates in Surgery Series, 2022, , 127-136.	0.0	1
1137	The impact of robotic technology on the learning curve for robot-assisted gastrectomy in the initial clinical application stage. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 4171-4180.	1.3	3
1139	Maagcarcinoom., 2011,, 355-359.		О

#	Article	IF	Citations
1140	Is the high level of expertise in open gastrectomy an essential requirement to start laparoscopic gastrectomy?. Korean Journal of Clinical Oncology, 2011, 7, 72-78.	0.1	0
1141	Multimodal Therapies for Upper Gastrointestinal Cancers – Past, Now, and Future. , 0, , .		0
1142	Gastric Cancer: Standard or Extended Lymphadenectomy?. , 2012, , 63-68.		0
1143	Evaluation of Pre-operative Clinical Prognosticator in Gastric Cancer-from the Viewpoint of Neoadjuvant Chemotherapy (NAC) Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of) Tj ETQq1 1	0 <b>.786</b> 314 i	rg <b>B</b> T /Overlo
1144	Surgical Treatment of Gastric Cancer Infiltrating the Esophago-gastric Junction., 2012,, 131-137.		0
1145	16 Maag en duodenum. , 2012, , 215-225.		O
1146	Follow-up and Treatment of Recurrence. , 2012, , 195-202.		3
1147	Treatment of Resectable Advanced Gastric Cancer. , 2012, , 89-94.		O
1148	Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e31-e34.	1.8	0
1149	Varying Lymphadenectomies for Gastric Adenocarcinoma in the East Compared with the West: Effect on Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 250-255.	1.8	2
1150	A Multidisciplinary Approach to the Treatment of Gastric Cancer: What Is the Role of the Surgeon?. Journal of Cancer Therapy, 2013, 04, 16-26.	0.1	0
1151	Surgical Management of Advanced Gastric Cancer. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2013, 13, 138.	0.1	1
1152	Laparoscopy: A Procedure no less than Laparotomy for Lymph Node Dissection in Total Gastrectomy for Gastric Carcinoma. World Journal of Laparoscopic Surgery, 2013, 6, 111-115.	0.2	0
1153	New treatments for gastric cancer: are they changing clinical practice?. Clinical Practice (London,) Tj ETQq $1\ 1\ 0.7$	'84314 rgE	3T_/Overlock
1154	Upper Gl Surgery. , 2013, , 319-334.		0
1156	Neoadjuvant chemotherapy in the combined treatment of gastric cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2014, 3, 13.	0.0	3
1157	Cancer of the Stomach and Gastroesophageal Junction. , 2014, , 1240-1270.e7.		1
1158	A Rare Case of Gastric Carcinosarcoma with Neuroendocrine Differentiation. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2014, 14, 121.	0.1	2

#	Article	IF	CITATIONS
1159	Neoadjuvant chemotherapy in localized resectable stomach cancer. Korean Journal of Clinical Oncology, 2014, 10, 1-5.	0.1	0
1160	MODIFIED D2 GASTRECTOMY - A FEASIBILITY STUDY IN INDIAN SCENARIO. Journal of Evidence Based Medicine and Healthcare, 2014, 1, 205-210.	0.0	0
1161	Standards for Surgical Therapy of Gastric Cancer. , 2015, , 73-91.		0
1164	Comparison of Different Methods of Multislice Spiral Computed Tomography for the Preoperative Gastric Cancer Staging. Surgical Science, 2015, 06, 427-435.	0.1	3
1165	Gastric Cancer: Molecular Mechanisms, Diagnosis, and Treatment., 2015,, 229-261.		0
1166	Lymphadenectomy—D1, D2, and D3. , 2015, , 185-197.		0
1167	Lymph node pick up by separate stations: Option or necessity. World Journal of Gastrointestinal Surgery, 2015, 7, 71.	0.8	2
1168	Optimized Lymphadenectomy for Early Gastric Cancer Based on the Analysis of 1141 Cases from a Single Institution. International Journal of Clinical Medicine, 2015, 06, 186-192.	0.1	0
1169	Robotic Applications in Advancing General Surgery. , 2015, , 377-390.		1
1170	Chirurgische Onkologie. , 2015, , 111-125.		0
1171	Surgical Trials for Gastric Cancer. , 2015, , 271-293.		0
1172	Gastric cancer and complications of relapsed disease. , 2015, , 89-98.		0
1174	Vascularizing lymph node dissection for advanced gastric cancer: A single-institution experience. World Journal of Gastroenterology, 2016, 22, 3813.	1.4	1
1175	Gastric Adenocarcinoma. , 2016, , 137-148.		0
1176	D1 versus Modified D2 Gastrectomy for Ca Stomachâ€"A Prospective and Comparative Study. Surgical Science, 2016, 07, 13-26.	0.1	0
1177	Function-Preserving Curative Gastrectomy Guided by ICG Fluorescence Imaging for Early Gastric Cancer., 2016,, 151-161.		0
1178	Diagnostik und Therapie des Magenkarzinoms., 2016,, 43-53.		0
1179	Gastroesophageal Cancer: Prognostic Factors and Treatment Results. Journal of Cancer Science and Clinical Oncology, 2016, 3, .	0.0	0

#	Article	IF	CITATIONS
1180	Gastric Cancer: Background and Clinical Evidence. , 2017, , 53-58.		0
1181	Neoadjuvant Treatment of Gastric Cancer. , 2017, , 149-157.		0
1182	Perioperative Systemtherapie bei Magen- und Kardiakarzinom. , 2017, , 79-84.		O
1183	Mesopancreas Excision for Pancreatic Cancer. , 2017, , 215-223.		0
1184	The staged treatment of locally advanced stomach cancer complicated by relapsing hemorrhage under conditions of the multi-speciality hospital. Russian Journal of Evidence-Based Gastroenterology, 2017, 6, 78.	0.3	O
1185	Lymphadenektomie bei Magenkarzinom und AEG. , 2017, , 101-109.		0
1186	Maagcarcinoom., 2017,, 333-342.		0
1187	Principles of Analysis. , 2017, , 151-162.		0
1188	Short Term Outcomes of Laparoscopic versus Open Distal Gastrectomy with D2 Lymph Nodes Dissection for Gastric Cancer: A Prospective Study. Surgical Science, 2017, 08, 334-347.	0.1	0
1189	Gastric Cancer in the Elderly. , 2017, , 1-26.		0
1190	Chemotherapy in Oesophagogastric Junctional Cancer. , 2017, , 139-148.		0
1192	Long-term survival differences in gastric cancer after D2 lymphadenectomy and an improved assessment of resectability. Journal of Clinical and Investigative Surgery, 2017, 2, 19-26.	0.1	O
1193	Is there a relation between the changes in tumor marker levels and lymph node dissection levels in gastric cancer?. Konuralp Tip Dergisi, 0, , 69-72.	0.1	0
1194	IMMUNITY SYSTEM AFTER EXTENDED SURGERIES IN PATIENTS WITH LOCALLY ADVANCED STOMACH CANCER. Avicenna Bulletin, 2018, 20, 52-57.	0.0	O
1195	Improved Survival after Implementation of Multidisciplinary Team Meetings, Perioperative Chemotherapy, Extended Lymphnode Dissection and Laparoscopic Surgery in the Treatment of Advanced Gastric Cancer. Journal of Cancer Therapy, 2018, 09, 106-117.	0.1	0
1196	Magentumoren. , 2018, , 215-253.		O
1197	Therapeutic Value of Lymph Node Dissection Along the Superior Mesenteric Vein and the Posterior Surface of the Pancreatic Head in Gastric Cancer Located in the Lower Third of the Stomach. Yonago Acta Medica, 2018, 61, 175-181.	0.3	3
1198	Magenkarzinom. Evidenzbasierte Chirurgie, 2018, , 65-88.	0.0	O

#	Article	IF	CITATIONS
1199	Chemotherapy versus chemoradiotherapy following surgery and neoadjuvant chemotherapy for resectable gastric cancer (CRITICS): an editorial. Digestive Medicine Research, 0, 1, 12-12.	0.2	1
1200	The Role of Radiation Therapy. , 2018, , 57-64.		0
1201	Clinical Aspects of Sentinel Lymph Node Biopsy in Gastric Cancer. Biomedical Journal of Scientific $\&$ Technical Research, 2018, 5, .	0.0	0
1202	Importance of Objective and Comprehensive Multi-Detector Row Computed Tomographic Evaluation of the Venous System in Gastrectomy. Japanese Journal of Gastroenterological Surgery, 2018, 51, 453-462.	0.0	1
1203	Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy?. World Journal of Gastrointestinal Oncology, 2018, 10, 271-281.	0.8	2
1204	Changing trends in clinico-pathologic characteristics and treatment outcomes in patients with gastric cancer: A single-center, public hospital, retrospective study. Korean Journal of Clinical Oncology, 2018, 14, 69-75.	0.1	O
1207	Landmark Trials in Selected Gastrointestinal Cancers. , 2019, , 123-168.		0
1208	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2019, , 1-28.		O
1209	Understanding Survival Disparities in Gastric Cancer. Oncology & Hematology Review, 2019, 15, 78.	0.2	1
1210	A History of Gastric Cancer Surgery and the Evidence for it. Nihon Rinsho Geka Gakkai Zasshi (Journal) Tj ETQq1 1	. 0,784314	1 rgBT /Over
1211	Prognostic significance of 14v-lymph node dissection to D2 dissection for lower-third gastric cancer. World Journal of Clinical Cases, 2019, 7, 2712-2721.	0.3	3
1212	Factors associated with metastasis in superior mesenteric vein lymph node in subtotal gastrectomy for gastric cancer: Retrospective case control study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 43-50.	0.7	5
1213	Gastric Adenocarcinoma., 2020,, 199-223.		0
1214	Prognostic value and nomograms of proximal margin distance in gastric cancer with radical distal gastrectomy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 186-196.	0.7	8
1216	D2 lymph node dissection confers little benefit on the overall survival of older patients with resectable gastric cancer: a propensity score-matching analysis of a multi-institutional dataset. Surgery Today, 2020, 50, 1434-1442.	0.7	9
1217	A Nomogram for Prediction of Survival in Patients After Gastrectomy Within Enhanced Recovery After Surgery (ERAS): A Single-Center Retrospective Study. Medical Science Monitor, 2020, 26, e926347.	0.5	3
1218	Mide kanseri hastalarında tümör lokalizasyonu ve lenf nodu tutulumunun prognoz ve sağkalıma etkisi. Adıyaman Üniversitesi Sağlık Bilimleri Dergisi, 0, , 248-257.	0.3	0
1219	Radical D2 gastrectomy with adjuvant chemotherapy for stage IB/II/III distal gastric cancers in the era of perioperative chemotherapy: A propensity matched comparison. American Journal of Surgery, 2022, 223, 1055-1062.	0.9	5

#	ARTICLE	IF	CITATIONS
1220	Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Trials, 2021, 22, 753.	0.7	1
1221	Lymph node ratio-based the ypTNrM staging system for gastric cancer after neoadjuvant therapy: a large population-based study. Surgery Today, 2022, 52, 783-794.	0.7	4
1222	TIM3+ cells in gastric cancer: clinical correlates and association with immune context. British Journal of Cancer, 2022, 126, 100-108.	2.9	12
1223	Normal and Abnormal Postoperative Imaging Findings after Gastric Oncologic and Bariatric Surgery. Korean Journal of Radiology, 2020, 21, 793.	1.5	O
1224	Lymph Node Mapping in Gastric Cancer Surgery: Current Status and New Horizons. Turkish Journal of Surgery, 2020, 36, 393-398.	0.1	0
1225	ĐʿĐ¸Đ¾Đ¿ÑĐ¸Ñ•ÑĐ¸Đ³Đ½Đ°Đ»ÑŒĐ½Ñ‹ÑĐ»Đ¸Đ¼Ñ"аÑ,Đ¸Ñ‡ĐµÑаиÑÑƒĐ·Đ»Đ¾Đ² Đ¿Ñ€Đ¸ Ñ€Đ°Đ½ĐЂ	/ <b>2Ф.µ</b> н Ñ	ĺ∰°ĐºĐμ Đ
1226	Gastric Cancer in the Elderly. , 2020, , 931-956.		0
1228	BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 1): AN UPDATE ON DIAGNOSIS, STAGING, ENDOSCOPIC TREATMENT AND FOLLOW-UP. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2020, 33, e1535.	0.5	8
1229	Laparoscopic D2 plus complete mesogastrium excision using the "enjoyable space―approach versus conventional D2 total gastrectomy for local advanced gastric cancer: short-term outcomes. Wideochirurgia I Inne Techniki Maloinwazyjne, 2020, 15, 58-69.	0.3	5
1230	Outcomes of Total and Subtotal Laparoscopic Gastrectomy with D2 Lymphadenectomy in Advanced Gastric Cancer in a Brazilian Hospital. Surgical Science, 2020, 11, 166-176.	0.1	O
1231	Experimental study on radiation damage of 1251 seeds implanted in canine gastric wall tissue. Journal of Cancer Research and Therapeutics, 2020, 16, 203.	0.3	5
1232	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2020, , 731-757.		1
1233	Left Dorsal Wall Anastomosis Compared with Parallel-Line Anastomosis for Intracorporeal Overlap Esophagojejunostomy during Laparoscopic Total Gastrectomy. Journal of Minimally Invasive Surgery, 2020, 23, 17-21.	0.2	0
1234	Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 86-97.	2.3	7
1235	History of the lymph node numbering system in the Japanese Classification of Gastric Carcinoma since 1962. Surgery Today, 2022, 52, 1515-1523.	0.7	9
1236	Current Status and Trends of Minimally Invasive Gastrectomy in Korea. Medicina (Lithuania), 2021, 57, 1195.	0.8	3
1237	Long-term Results of Endoscopic Submucosal Dissection (ESD) for the Treatment of Early Gastric Cancer (EGC) in a High-volume Latin American Center. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2021, 31, 165-169.	0.4	3
1238	Positive impact of adding No.14v lymph node to D2 dissection on survival for distal gastric cancer patients after surgery with curative intent. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 580-7.	0.7	11

#	ARTICLE	IF	CITATIONS
1239	Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296). Gastrointestinal Cancer Research: GCR, 2012, 5, 191-7.	0.8	2
1240	Monitoring of peri-distal gastrectomy carbohydrate antigen 19-9 level in gastric juice and its significance. International Journal of Clinical and Experimental Medicine, 2014, 7, 230-8.	1.3	8
1241	Laparoscopy-assisted versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 1490-9.	1.3	20
1242	Outcome analysis of laporoscopic D1 and D2 dissection in patients 70 years and older with gastric cancer. International Journal of Clinical and Experimental Medicine, 2014, 7, 3501-11.	1.3	4
1243	Application of laparoscopy in the diagnosis and treatment of gastric cancer. Annals of Translational Medicine, 2015, 3, 126.	0.7	2
1244	Surgical interventions for gastric cancer: a review of systematic reviews. International Journal of Clinical and Experimental Medicine, 2015, 8, 13657-69.	1.3	6
1245	Survival prognosis and clinicopathological features of the lymph nodes along the left gastric artery in gastric cancer: implications for D2 lymphadenectomy. International Journal of Clinical and Experimental Pathology, 2015, 8, 14365-73.	0.5	3
1246	Impact of the 8th edition of the AJCC TNM classification on gastric cancer prognosis-study of a western cohort. Ecancermedical science, 2020, 14, 1124.	0.6	1
1247	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience, 2020, 14, 1126.	0.6	3
1248	Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. Journal of Gastrointestinal Oncology, 2020, 11, 952-963.	0.6	0
1249	Angiogenesis is associated with an attenuated tumor microenvironment, aggressive biology, and worse survival in gastric cancer patients. American Journal of Cancer Research, 2021, 11, 1659-1671.	1.4	7
1250	Magenkarzinom., 2022, , 259-267.		0
1251	Extent of gastrectomy and lymphadenectomy for gastric adenocarcinoma. Surgical Oncology, 2022, 40, 101689.	0.8	3
1252	Health-Related Quality of Life in Locally Advanced Gastric Cancer: A Systematic Review. Cancers, 2021, 13, 5934.	1.7	9
1253	Cytoreductive Surgery for Peritoneal Carcinomatosis from Gastric Cancer: Technical Details. Journal of Clinical Medicine, 2021, 10, 5263.	1.0	2
1254	nPTD classification: an updated classification of gastric cancer location for function preserving gastrectomy based on physiological lymphatic flow. BMC Cancer, 2021, 21, 1231.	1.1	2
1255	Magenkarzinom: Neue molekulare Konzepte. , 0, , .		3
1256	External Validation of a Nomogram Developed for Predicting Overall Survival in Gastric Cancer Patients with Insufficient Number of Examined Lymph Nodes. Sisli Etfal Hastanesi Tip Bulteni, 2021, 56, 137-144.	0.1	0

#	Article	IF	CITATIONS
1257	Limited Clinical Significance of Splenectomy and Splenic Hilar Lymph Node Dissection for Type 4 Gastric Cancer. Journal of Gastric Cancer, 2021, 21, 392.	0.9	3
1258	Laparoscopic gastrectomy for gastric cancer: has the time come for considered it a standard procedure?. Surgical Oncology, 2022, 40, 101699.	0.8	6
1259	Elevated carbohydrate antigen 125 post-operation as a prognostic marker in gastric cancer patients with stage II–III. Translational Cancer Research, 2020, 9, 5200-5208.	0.4	0
1260	Immediate and Long-Term Results of the Spleen-Preserved Operations in the Surgical Treatment of Gastric Cancer. Journal of Experimental and Clinical Surgery, 2020, 13, 227-232.	0.1	1
1261	Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. Journal of Gastrointestinal Oncology, 2020, 11, 952-963.	0.6	0
1262	Impact of the 8th edition of the AJCC TNM classification on gastric cancer prognosis—study of a western cohort. Ecancermedicalscience, 2020, 14, 1124.	0.6	7
1263	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience, 2020, 14, 1126.	0.6	3
1264	D2 Lymphadenectomy as an Independent Prognostic Factor in Gastric Cancer. ARS Medica Tomitana, 2020, 26, 181-187.	0.0	0
1266	Minimally invasive versus open surgery for gastric cancer in Turkish population. Turkish Journal of Surgery, 2021, 37, 142-150.	0.1	0
1267	Surgical technique of suprapancreatic D2 lymphadenectomy focusing on the posterior hepatic plexus for advanced gastric cancer. Langenbeck's Archives of Surgery, 2022, 407, 871-877.	0.8	0
1268	A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer. International Journal of Hyperthermia, 2022, 39, 239-245.	1.1	3
1269	Significance of Lymph Node Metastasis in the Treatment of Gastric Cancer and Current Challenges in Determining the Extent of Metastasis. Frontiers in Oncology, 2021, 11, 806162.	1.3	19
1270	Reverse rolling-mat type lymph node dissection is the key step to solve the operative difficulties in hand-assisted laparoscopic D2 radical gastrectomy. BMC Surgery, 2022, 22, 2.	0.6	0
1271	Postoperative mortality and morbidity after D2 lymphadenectomy for gastric cancer: A retrospective cohort study. World Journal of Gastroenterology, 2022, 28, 381-398.	1.4	12
1272	Survival impact of compliance in extra-perigastric lymphadenectomy for gastric cancer: 20 years of real-world data from a single institution. Surgery, 2022, 171, 948-954.	1.0	4
1273	Risk Assessment and Preventive Treatment for Peritoneal Recurrence Following Radical Resection for Gastric Cancer. Frontiers in Oncology, 2021, 11, 778152.	1.3	2
1274	Clinical Features and Survival of Young Adults with Stage IV Gastric Cancer: a Japanese Population-Based Study. Journal of Gastrointestinal Cancer, 2023, 54, 56-61.	0.6	2
1275	Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer., 2022, 10, e004047.		12

#	Article	IF	Citations
1276	Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials. Gastric Cancer, 2022, 25, 640-651.	2.7	10
1277	ALK, NUT, and TRK Do Not Play Relevant Roles in Gastric Cancerâ€"Results of an Immunohistochemical Study in a Large Series. Diagnostics, 2022, 12, 429.	1.3	1
1278	Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles. Medicine (United States), 2022, 101, e28620.	0.4	5
1279	A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines. Journal of Gastric Cancer, 2022, 22, 3.	0.9	34
1280	Magen – Duodenum. , 2022, , 161-192.		0
1281	Chirurgische Onkologie., 2022,, 369-381.		0
1282	Impact of the Deep Neuromuscular Block on Oncologic Quality of Laparoscopic Surgery in Obese Gastric Cancer Patients: A Randomized Clinical Trial. Journal of the American College of Surgeons, 2022, 234, 326-339.	0.2	2
1283	Effect of Shengbai Decoction on Chemotherapy-Induced Myelosuppression and Survival of Gastric Cancer Patients After Radical Resection: A Retrospective Study. Medical Science Monitor, 2022, 28, e935936.	0.5	0
1284	Superior pancreatic lymphadenectomy with portal vein priority <i>via</i> posterior common hepatic artery approach in laparoscopic radical gastrectomy. World Journal of Clinical Cases, 2022, 10, 1834-1842.	0.3	0
1285	Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for undifferentiated-type early gastric cancer meeting the expanded criteria: a systematic review and meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 3686-3697.	1.3	10
1286	NIR Activated Upper Critical Solution Temperature Polymeric Micelles for Trimodal Combinational Cancer Therapy. Biomacromolecules, 2022, 23, 937-947.	2.6	9
1287	Radiomics in Gastric Cancer: First Clinical Investigation to Predict Lymph Vascular Invasion and Survival Outcome Using 18F-FDG PET/CT Images. Frontiers in Oncology, 2022, 12, 836098.	1.3	7
1288	The Amount and Concentration of Drain Amylase Together Predict Postoperative Pancreatic Fistula after Gastric Cancer Surgery More Accurately than the Concentration Alone. Oncology, 2022, , .	0.9	0
1289	Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 261-267.	2.3	7
1290	Clinical Application of Indocyanine Green Fluorescence Technology in Laparoscopic Radical Gastrectomy. Frontiers in Oncology, 2022, 12, 847341.	1.3	6
1291	Surgical Management of Gastric Cancer. JAMA Surgery, 2022, 157, 446.	2.2	73
1292	Comparison of Standard D2 and Limited Lymph Node Dissection in Elderly Patients with Advanced Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 5076-5082.	0.7	4
1294	Evolution of treatment in gastric cancer- a systematic review. Journal of the Egyptian National Cancer Institute, 2022, 34, 12.	0.6	5

#	Article	IF	CITATIONS
1295	Anatomy and assessment of a modified technique during totally robotic distal gastrectomy: A retrospective cohort study. Annals of Medicine and Surgery, 2022, 75, 103466.	0.5	0
1296	Near-Infrared Fluorescence Image-Guided Surgery in Esophageal and Gastric Cancer Operations. Surgical Innovation, 2022, 29, 540-549.	0.4	8
1297	Laparoscopic vs. Open Gastrectomy for Locally Advanced Gastric Cancer: A Propensity Score-Matched Retrospective Case-Control Study. Current Oncology, 2022, 29, 1840-1865.	0.9	13
1298	Laparoscopic versus open subtotal gastrectomy for locally advanced gastric cancer: A retrospective analysis from a single institution. Asian Journal of Surgery, 2023, 46, 222-227.	0.2	1
1299	Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy. JAMA Network Open, 2022, 5, e225557.	2.8	15
1300	Early and late recurrences in lymph node-negative gastric cancer: a retrospective cohort study. Annals of Saudi Medicine, 2021, 41, 336-349.	0.5	4
1301	Gastric cancer: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 541-571.	0.1	2
1302	Dynamic Prediction of Survival after Curative Resection of Gastric Adenocarcinoma: A landmarking-based analysis. European Journal of Surgical Oncology, 2021, , .	0.5	0
1303	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. Journal of Surgical Oncology, 2022, 125, 621-630.	0.8	9
1304	Data Set for Reporting Carcinoma of the Stomach in Gastrectomy. Archives of Pathology and Laboratory Medicine, 2022, 146, 1072-1083.	1.2	5
1305	Radiomics model based on preoperative 18F-fluorodeoxyglucose PET predicts N2-3b lymph node metastasis in gastric cancer patients. Nuclear Medicine Communications, 2022, 43, 340-349.	0.5	3
1307	Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer. Journal of Gastric Cancer, 2022, 22, 107.	0.9	3
1308	Is D2 Lymphadenectomy Necessary in Elderly Gastric Cancer Patients? A Retrospective Study. International Surgery, 2022, 106, 150-156.	0.0	2
1309	Misclassification of nodal stage in gastric cancer: 16 lymph nodes is not enough. Surgical and Experimental Pathology, 2022, 5, .	0.2	4
1310	Open and minimally invasive gastrectomy in Eastern and Western patient populations: A review of the literature and reasons for differences in outcomes. Journal of Surgical Oncology, 2022, 126, 279-291.	0.8	3
1311	Letter comments on: D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial. European Journal of Cancer, 2022, 168, 141-142.	1.3	0
1312	Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications. Current Cancer Drug Targets, 2022, 22, .	0.8	3
1313	Assessment of Carbon Nanoparticle Suspension Lymphography–Guided Distal Gastrectomy for Gastric Cancer. JAMA Network Open, 2022, 5, e227739.	2.8	13

#	Article	IF	Citations
1314	The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis. World Journal of Surgical Oncology, 2022, 20, 123.	0.8	3
1322	Predictors of Metastatic Lymph Nodes at Preoperative Staging CT in Gastric Adenocarcinoma. Tomography, 2022, 8, 1196-1207.	0.8	1
1323	The Basic Study of Liposome in Temperature-Sensitive Gel at Body Temperature for Treatment of Peritoneal Dissemination. Gels, 2022, 8, 252.	2.1	3
1324	Progress and remaining challenges in comprehensive gastric cancer treatment. , 2022, 1, .		3
1325	Patterns of Multimodality Management of Gastric Cancerâ€"Single Institutional Experience of 372 Cases From a Tertiary Care Center in North India. Frontiers in Oncology, 2022, 12, 877493.	1.3	1
1326	Comparison Between Linear Stapler and Circular Stapler After Laparoscopic-Assisted Distal Gastrectomy in Patients With Gastric Cancer. Frontiers in Surgery, 2022, 9, .	0.6	3
1327	Boag model versus Cox model in cancer survival analysis: a controversy. Tenri Medical Bulletin, 2010, 13, 88-104.	0.1	0
1328	Development of computer programs for cancer survival analysis based on the Boag model and its extensions. Tenri Medical Bulletin, 2011, 14, 93-107.	0.1	1
1329	Outcomes of surgical treatment of non-metastatic gastric cancer in patients aged 70 and older: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2022, 48, 1882-1894.	0.5	3
1330	Evaluation of Preliminary Results Of Laparoscopic and Open Surgery in Gastrectomy For Gastric Cancer: Single-Center Experience. Journal of Contemporary Medicine, 0, , .	0.1	0
1333	Surgical and oncological outcomes of D1 versus D2 gastrectomy among elderly patients treated for gastric cancer. Scandinavian Journal of Surgery, 2022, 111, 145749692210961.	1.3	2
1334	Contrast-enhanced CT based radiomics in the preoperative prediction of perineural invasion for patients with gastric cancer. European Journal of Radiology, 2022, 154, 110393.	1.2	8
1335	Esophageal and gastric cancer. , 2023, , 349-357.		0
1337	Impact of Subclassification of Serosal Invasion on the Survival of Patients With T4a Gastric Cancer. In Vivo, 2022, 36, 1923-1929.	0.6	1
1338	Adjuvant Chemotherapy in Node-Negative Advanced Gastric Cancer Patients. Journal of Oncology, 2022, 2022, 1-7.	0.6	1
1339	Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 0, , .	0.7	1
1340	Laparoscopic versus Open Surgery for Gastric Cancer in Western Countries: A Systematic Review and Meta-Analysis of Short- and Long-Term Outcomes. Journal of Clinical Medicine, 2022, 11, 3590.	1.0	9
1341	Survival trends of patients with nonâ€metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates. Cancer Communications, 2022, 42, 648-662.	3.7	7

#	Article	IF	CITATIONS
1342	Lymph node metastases rate of locoregional and non-locoregional lymph node stations in gastric cancer. Journal of Gastrointestinal Oncology, 2022, 13, 1605-1615.	0.6	3
1343	Prognostic significance of the preoperative hemoglobin to albumin ratio for the short-term survival of gastric cancer patients. World Journal of Gastrointestinal Surgery, 2022, 14, 580-593.	0.8	3
1344	Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection. Frontiers in Oncology, 0, 12, .	1.3	0
1345	Role of prophylactic HIPEC in non-metastatic, serosa-invasive gastric cancer: a literature review. Pleura and Peritoneum, 2022, 7, 103-115.	0.5	2
1346	Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives. Biomedicines, 2022, 10, 1614.	1.4	5
1347	Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts. European Journal of Cancer, 2022, 173, 95-104.	1.3	9
1348	The Impact of Perioperative Events on Cancer Recurrence and Metastasis in Patients after Radical Gastrectomy: A Review. Cancers, 2022, 14, 3496.	1.7	4
1349	Survival of patients with gastric cancer surgically treated at the National Cancer Center of China from 2011 to 2018 according to stage at diagnosis. Journal of the National Cancer Center, 2022, , .	3.0	1
1350	Prognostic nomograms for gastric carcinoma after surgery to assist decision-making for postoperative treatment with chemotherapy cycles <9 or chemotherapy cycles ≥9. Frontiers in Surgery, 0, 9, .	0.6	2
1351	Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 3940.	1.7	5
1352	Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer. British Journal of Cancer, 2022, 127, 1709-1717.	2.9	13
1353	A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy. Frontiers in Oncology, 0, $12$ , .	1.3	4
1354	Validity and safety of laparoscopic gastrectomy with D1+ lymphadenectomy for very elderly advanced gastric cancer patients; retrospective cohort study. Japanese Journal of Clinical Oncology, $0$ , , .	0.6	1
1355	Efficacy and safety of indocyanine green tracer-guided lymph node dissection in minimally invasive radical gastrectomy for gastric cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	2
1356	Impact of Textbook Oncologic Outcome Attainment on Survival After Gastrectomy: A Review of the National Cancer Database. Annals of Surgical Oncology, 2022, 29, 8239-8248.	0.7	9
1357	Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma. Annals of Surgical Oncology, 2022, 29, 8653-8661.	0.7	5
1358	Viszeralchirurgie., 2022,, 223-437.		0
1359	Tumor Location Causes Different Recurrence Patterns in Remnant Gastric cancer Journal of Gastric Cancer, 0, 22, .	0.9	0

#	Article	IF	CITATIONS
1360	Is D2 laparoscopic gastrectomy essential for elderly patients with advanced gastric cancer?. Journal of Gastrointestinal Oncology, 2022, .	0.6	0
1361	Model based on preoperative clinical characteristics to predict lymph node metastasis in patients with gastric cancer. Frontiers in Surgery, 0, 9, .	0.6	1
1362	Fifty years of progress in gastric cancer. Journal of Surgical Oncology, 2022, 126, 865-871.	0.8	0
1363	Real-time Tracking and Classification of Tumor and Nontumor Tissue in Upper Gastrointestinal Cancers Using Diffuse Reflectance Spectroscopy for Resection Margin Assessment. JAMA Surgery, 2022, 157, e223899.	2.2	9
1364	Emergency Medicine with Advanced Surgery Protocols: A Review. Journal of Environmental and Public Health, 2022, 2022, 1-6.	0.4	1
1365	Determination of the extent of dissection in early gastric cancer based on lymph node station power index. BJS Open, 2022, 6, .	0.7	2
1366	Surgical and oncological outcomes of robotic- versus laparoscopic-assisted distal gastrectomy with D2 lymphadenectomy for advanced gastric cancer: a propensity score‑matched analysis of 1164 patients. World Journal of Surgical Oncology, 2022, 20, .	0.8	5
1367	Initial Experience with Robotic Gastrectomy in Patients with Gastric Cancer: An Assessment of Short-Term Surgical Outcomes. Kurume Medical Journal, 2022, , .	0.0	O
1368	The DOLFIN method: a novel laparoscopic Billroth-I gastroduodenostomy for gastric cancer with duodenal invasion. Langenbeck's Archives of Surgery, 0, , .	0.8	0
1369	Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial. Gastric Cancer, 2022, 25, 1060-1072.	2.7	8
1370	Use of folic acid nanosensors with excellent photostability for hybrid imaging. Journal of Zhejiang University: Science B, 2022, 23, 784-790.	1.3	0
1371	An ensemble method of the machine learning to prognosticate the gastric cancer. Annals of Operations Research, 2023, 328, 151-192.	2.6	8
1372	Surgical considerations and outcomes of minimally invasive approaches for gastric cancer resection. Cancer, 2022, 128, 3910-3918.	2.0	3
1373	Leveraging the Multidisciplinary Tumor Board for Dissemination of Evidence-Based Recommendations on the Staging and Treatment of Gastric Cancer: A Pilot Study. Annals of Surgical Oncology, 2023, 30, 1120-1129.	0.7	1
1374	Understanding Cancer Cachexia and Its Implications in Upper Gastrointestinal Cancers. Current Treatment Options in Oncology, 2022, 23, 1732-1747.	1.3	8
1375	Developing and validating nomograms for predicting the survival in patients with clinical local-advanced gastric cancer. Frontiers in Oncology, 0, 12, .	1.3	1
1376	Impact of examined lymph node number on accurate nodal staging and long-term survival of resected Siewert type II-III adenocarcinoma of the esophagogastric junction: A large population-based study. Frontiers in Oncology, 0, 12, .	1.3	0
1377	A 9â€'gene expression signature to predict stage development in resectable stomach adenocarcinoma. BMC Gastroenterology, 2022, 22, .	0.8	0

#	Article	IF	CITATIONS
1378	Borrmann Type Predicts Response to Preoperative Therapy in Advanced Gastric Cancer. Journal of Gastrointestinal Cancer, $0, \dots$	0.6	2
1380	The Perioperative and Operative Management of Esophageal and Gastric Cancer. Surgical Oncology Clinics of North America, 2023, 32, 65-81.	0.6	4
1381	Minimally invasive radical hysterectomy and the importance of avoiding cancer cell spillage for early-stage cervical cancer: a narrative review. Journal of Gynecologic Oncology, 2023, 34, .	1.0	7
1382	The Role of Surgery in the Management of Gastric Cancer: State of the Art. Cancers, 2022, 14, 5542.	1.7	6
1383	Lymphadenectomy in Proximal Gastric Cancer—Location, Location, Location. JAMA Surgery, 2023, 158, 18.	2.2	1
1384	Tumor Depth Prediction of Gastric Cancer With a T4 Score. Cancer Diagnosis & Prognosis, 2022, 2, 641-647.	0.3	0
1385	Role of Adjuvant Radiotherapy in Gastric Cancer. Journal of Gastric Cancer, 2023, 23, 194.	0.9	1
1386	Metastatic lymph nodes and prognosis assessed by the number of retrieved lymph nodes in gastric cancer. World Journal of Gastrointestinal Surgery, 0, 14, 1230-1249.	0.8	O
1387	Total Extended Gastrectomy in Advanced Gastric Cancer – Clinical Case. Journal of Biomedical and Clinical Research, 2022, 15, 182-186.	0.1	1
1388	Long-term outcomes and clinical safety of expanded indication early gastric cancer treated with endoscopic submucosal dissection versus surgical resection: a meta-analysis. BMJ Open, 2022, 12, e055406.	0.8	3
1389	Three-year outcomes of robotic gastrectomy versus laparoscopic gastrectomy for the treatment of clinical stage I/II gastric cancer: a multi-institutional retrospective comparative study. Surgical Endoscopy and Other Interventional Techniques, 2023, 37, 2858-2872.	1.3	6
1391	Advances in surgical techniques for gastric cancer: Indocyanine green and near-infrared fluorescence imaging. Is it ready for prime time?. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 587-591.	0.7	0
1392	Principles and Practice of Surgery in Gynaecological Cancer. , 2022, , 69-76.		0
1393	Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. Current Oncology, 2023, 30, 875-896.	0.9	8
1394	Chylous Ascites After Gastric Cancer Surgery: Risk Factors and Treatment Results. Journal of Gastric Cancer, 0, 23, .	0.9	0
1395	Prognostic effect of excessive chemotherapy cycles for stage II and III gastric cancer patients after D2 + gastrectomy. World Journal of Gastrointestinal Surgery, 0, 15, 32-48.	0.8	2
1396	Safety and efficacy of indocyanine green near-infrared fluorescent imaging-guided lymph node dissection during robotic gastrectomy for gastric cancer: a systematic review and meta-analysis. Minimally Invasive Therapy and Allied Technologies, 2023, 32, 240-248.	0.6	2
1397	Is there still a place for radiotherapy in gastric cancer?. Current Opinion in Pharmacology, 2023, 68, 102325.	1.7	2

#	Article	IF	CITATIONS
1398	The evolution of treatment for resectable gastric cancer. , 2023, 2, 100008.		O
1399	Optimal extent of lymph node dissection in gastric cancer. Frontiers in Surgery, 0, 9, .	0.6	0
1400	Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. Journal of Gastric Cancer, 2023, 23, 3.	0.9	66
1401	Correlation Analysis between Postoperative Complications and Long-Term Survival after Radical Resection of Gastric Cancer. Advances in Clinical Medicine, 2023, 13, 1275-1286.	0.0	0
1402	Surgery Matters: Progress in Surgical Management of Gastric Cancer. Current Treatment Options in Oncology, 2023, 24, 108-129.	1.3	4
1403	Total Gastrectomy with D2 Lymph Node Dissection. , 2013, , 148-155.		0
1404	Dynamic Nomogram for Predicting Long-Term Survival in Terms of Preoperative and Postoperative Radiotherapy Benefits for Advanced Gastric Cancer. International Journal of Environmental Research and Public Health, 2023, 20, 2747.	1.2	0
1405	Reply to: "Letter regarding  Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma' ― Journal of Hepatology, 2023, 78, e170-e172.	1.8	0
1406	Đre Multivisceral Resections for Gastric Cancer Acceptable: Experience from a High Volume Center and Extended Literature Review?. The Surgery Journal, 2023, 09, e28-e35.	0.3	0
1407	Current standards of surgical management of gastric cancer: an appraisal. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	1
1408	The Influence of Group No.8p Lymph Node Dissection on the Prognosis of Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2023, 27, 887-894.	0.9	0
1409	Endoscopic fluorescent lymphography for gastric cancer. World Journal of Gastrointestinal Endoscopy, 0, 15, 32-43.	0.4	1
1410	Complement receptor <scp>C5aR1</scp> blockade reprograms tumorâ€associated macrophages and synergizes with <scp>antiâ€PD</scp> â€1 therapy in gastric cancer. International Journal of Cancer, 2023, 153, 224-237.	2.3	5
1411	Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Surgery, $0$ , $10$ , .	0.6	4
1412	Improved survival after laparoscopic compared to open gastrectomy for advanced gastric cancer: a Swedish population-based cohort study. Gastric Cancer, 2023, 26, 467-477.	2.7	4
1413	Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study. Frontiers in Oncology, 0, 13, .	1.3	0
1414	A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma. Cancers, 2023, 15, 1628.	1.7	2
1415	Tranditional Roux-en-Y vs Uncut Roux-en-Y in Laparoscopic Distal Gastrectomy: a Randomized Controlled Study. Journal of Gastrointestinal Surgery, 2023, 27, 1098-1105.	0.9	2

#	Article	IF	CITATIONS
1416	Less Than Ten: Defining the Role of Splenic Hilar Lymph Node Dissection in Gastric Cancer. Annals of Surgical Oncology, $0$ , , .	0.7	2
1417	Current Status and Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Journal of Biosciences and Medicines, 2023, 11, 156-170.	0.1	0
1418	Comparison of long-term quality of life between Billroth-I and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: a randomized controlled trial. Chinese Medical Journal, 2023, 136, 1074-1081.	0.9	4
1419	Two decades of gastric and gastroesophageal junction cancer surgery. Journal of Cancer Research and Clinical Oncology, 2023, 149, 7679-7688.	1.2	1
1420	Systematic review and meta-analysis of the outcomes following neoadjuvant therapy in upfront resectable gastric cancers compared to surgery alone in phase III randomised controlled trials. Journal of Gastrointestinal Surgery, 2023, 27, 1261-1276.	0.9	0
1421	Pattern of Distribution of Lymph Node Metastases in Individual Stations in Middle and Lower Gastric Carcinoma. Cancers, 2023, 15, 2139.	1.7	2
1438	Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nature Reviews Clinical Oncology, 2023, 20, 453-469.	12.5	7
1439	Current standards of lymphadenectomy in gastric cancer. Updates in Surgery, 2023, 75, 1751-1758.	0.9	3
1454	Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	4
1458	Magenkarzinom. Springer Reference Medizin, 2023, , 1-49.	0.0	0
1483	Clinical Management of Gastric Cancer Treatment Regimens. Current Topics in Microbiology and Immunology, 2023, , 279-304.	0.7	0